Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 13/20 | 0.51 |
| ▸ | TLR1 | Q15399 | 12/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rolicyprine SCHEMBL30616025 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPSR1TLR2TLR1MEN1 | |
| SCHEMBL6154005 | 0.76 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1TLR2TLR1EPHX2 | |
| SCHEMBL6153775 | 0.76 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1TLR2TLR1EPHX2 | |
| SCHEMBL7980208 | 0.76 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1TLR2TLR1EPHX2 | |
| SCHEMBL3457343 | 0.76 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1TLR2TLR1EPHX2 | |
| SCHEMBL19592035 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2NPSR1TLR2TLR1EPHX2 | |
| SCHEMBL25023345 | 0.74 | TLR2 (0.62) | SMN1; SMN2NPSR1TLR2TLR1KDM1A | |
| SCHEMBL2222173 | 0.74 | POLB (0.63) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2222163 | 0.74 | POLB (0.63) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22178828 | 0.73 | TLR2 (0.60) | SMN1; SMN2NPSR1TLR2TLR1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1198 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2012116278-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1725222-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | Pharmacia Corporation (US) | 2006-11-29 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| WO-2005084654-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | PHARMACIA CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12290597-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12171723-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4422607-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | KIAKOS KONSTANTINOS (AT) | 2024-04-23 | — | — | US | disclosed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050317-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4304554-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | Aquestive Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230414452-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11845759-B2 | Opioid compounds and uses thereof | RHODES TECHNOLOGIES (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4277611-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11806311-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773107-B2 | Opioid ketal compounds and uses thereof | RHODES TECHNOLOGIES (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2023-09-07 | — | — | US | disclosed |
| US-11731979-B2 | Opioid ketal compounds and uses thereof | RHODES TECHNOLOGIES (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4208155-A1 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20230149304-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230145752-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023076281-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230131450-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| EP-3258925-B1 | METHODS AND COMPOSITIONS FOR DECREASING GASTRIC EMPTYING | PURDUE PHARMA LP (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | Pike Therapeutics Inc. (CA) | 2023-02-23 | — | — | US | disclosed |
| EP-4135712-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | Pike Therapeutics, Inc. (CA) | 2023-02-22 | — | — | EP | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| US-11541002-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| CN-115515582-A | Combination therapy for acute myeloid leukemia | 细胞基因公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115485262-A | Hypoxia inducible factor-2 (alpha) inhibitors and their use in the treatment of disease | 尼坎治疗公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220347117-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2022-11-03 | — | — | US | disclosed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-4058029-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022192476-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-115043943-A | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies | 综合医院公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022187556-A1 | THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING MAGNETIZABLE NANOPARTICLES | VRG STEM CELL SERVICES INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4051235-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220265667-A1 | ETIFOXINE FOR USE IN THE TREATMENT OF DISEASES RELATED TO ACTIVATED MAST CELLS | MC SCIENCES UG (DE) | 2022-08-25 | — | — | US | disclosed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| WO-2022155544-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| CN-114681462-A | Formulations/compositions comprising BTK inhibitors | 詹森药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-4009980-A1 | ETIFOXINE FOR USE IN THE TREATMENT OF DISEASES RELATED TO ACTIVATED MAST CELLS | MC Sciences UG (DE) | 2022-06-15 | — | — | EP | disclosed |
| CN-107849142-B | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies | 综合医院公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3590925-B1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| CN-114040915-A | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | 里伯赛恩斯有限责任公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-113874350-A | tetrahydro-1H-cyclopenta [ CD ] indene derivatives as hypoxia inducible factor-2 (alpha) inhibitors | 尼坎治疗公司 | 2021-12-31 | — | — | CN | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| WO-2021209815-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS, INC. (CA) | 2021-10-21 | — | — | WO | disclosed |
| US-20210322447-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS INC (CA) | 2021-10-21 | — | — | US | disclosed |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-11130765-B2 | Opioid ketal compounds and uses thereof | RHODES TECHNOLOGIES (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11091496-B2 | Opioid ketal compounds and uses thereof | RHODES TECHNOLOGIES (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210220343-A1 | TREATMENT OF BURN PAIN BY TRPV1 MODULATORS | PURDUE PHARMA LP (US) | 2021-07-22 | — | — | US | disclosed |
| WO-2021097247-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210145731-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2021087359-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3811371-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | Aquestive Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10988480-B2 | Opioid ketal compounds and uses thereof | RHODES TECHNOLOGIES (US) | 2021-04-27 | — | — | US | disclosed |
| US-20210061815-A1 | NOVEL OPIOID COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210060040-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| WO-2021039972-A1 | UROTHELIAL CELL INDUCTION AGENT AND METHOD FOR INDUCING UROTHELIAL CELLS | セルアクシア株式会社 | 2021-03-04 | — | — | WO | disclosed |
| WO-2021023809-A1 | ETIFOXINE FOR USE IN THE TREATMENT OF DISEASES RELATED TO ACTIVATED MAST CELLS | MC SCIENCES UG (DE) | 2021-02-11 | — | — | WO | disclosed |
| EP-3755704-A1 | NOVEL OPIOID COMPOUNDS AND USES THEREOF | Rhodes Technologies Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200399220-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF | KIAKOS KONSTANTINOS (AT) | 2020-12-24 | — | — | US | disclosed |
| US-20200345624-A1 | Nanopore Delivery Device | HUDSON LEE EDWARD (US) | 2020-11-05 | — | — | US | disclosed |
| WO-2019097080-A9 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACITIVTY AND USES THEROF | KIAKOS KONSTANTINOS (AT) | 2020-10-15 | — | — | WO | disclosed |
| US-20200325146-A1 | OPIOID KETAL COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200317684-A1 | OPIOID KETAL COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2020-10-08 | — | — | US | disclosed |
| EP-3713916-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACITIVTY AND USES THEROF | Kiakos, Konstantinos (AT) | 2020-09-30 | — | — | EP | disclosed |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2020-09-15 | — | — | US | disclosed |
| EP-1511494-B1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | UNIMED PHARMACEUTICALS LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3692989-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20200239460-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA LP (US) | 2020-07-30 | — | — | US | disclosed |
| EP-2506837-B1 | SPIDER SILK PARTICLES FOR CONTROLLED AND SUSTAINED DELIVERY OF COMPOUNDS | AMSILK GMBH (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-20200197310-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA | 2020-06-25 | — | — | US | disclosed |
| US-10632134-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10619209-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20200101009-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2020-04-02 | — | — | US | disclosed |
| US-10583086-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-10584110-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20200069681-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20200048269-A1 | OPIOID KETAL COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2020-02-13 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-10450308-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190292149-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2019165298-A1 | NOVEL OPIOID COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2019-08-15 | — | — | US | disclosed |
| US-20190249255-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-08-15 | — | — | US | disclosed |
| EP-2616441-B1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10369340-B2 | Device and method for sustained release of low water solubility therapeutic agent in solubilizer | NANOMEDICAL SYSTEMS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| CN-109970708-A | Cannibinoid receptor modulators | 艾尼纳制药公司 | 2019-07-05 | — | — | CN | disclosed |
| EP-2419091-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3049082-B1 | TREATMENT OF BURN PAIN BY TRPV1 MODULATORS | PURDUE PHARMA LP (US) | 2019-05-22 | — | — | EP | disclosed |
| CN-103492369-B | Cannabinoid receptor modulators | 艾尼纳制药公司 | 2019-03-29 | — | — | CN | disclosed |
| US-10231938-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3452597-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | Wave Life Sciences Ltd. (SG) | 2019-03-13 | — | — | EP | disclosed |
| US-20190054024-A1 | Solid Dosage Forms | HUMANWELL PHARMACEUTICAL US, Inc. (US) | 2019-02-21 | — | — | US | disclosed |
| US-10202344-B2 | Aryl substituted indoles and the use thereof | PURDUE PHARMA L.P. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2019-01-03 | — | — | US | disclosed |
| US-20190002984-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2019-01-03 | — | — | US | disclosed |
| EP-2340271-B1 | POLYMER-BIOACTIVE AGENT CONJUGATES | POLYACTIVA PTY LTD (AU) | 2018-12-05 | — | — | EP | disclosed |
| US-10143696-B2 | Methods and compositions for decreasing gastric emptying | PURDUE PHARMA L.P. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180303809-A1 | TREATMENT OF BURN PAIN BY TRPV1 MODULATORS | PURDUE PHARMA LP (US) | 2018-10-25 | — | — | US | disclosed |
| EP-3385252-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-2528893-B1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180280386-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-10-04 | — | — | US | disclosed |
| US-20180271788-A1 | VESICLE CONTAINING METALLIC NANOPARTICLE AND METHOD FOR PRODUCTION THEREOF | The United States of America, as represented by the Secretary, Department of Health and | 2018-09-27 | — | — | US | disclosed |
| US-20180265524-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2018-09-20 | — | — | US | disclosed |
| US-20180251840-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIV VIRGINIA PATENT FOUNDATION (US) | 2018-09-06 | — | — | US | disclosed |
| US-10059675-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2018-07-26 | — | — | US | disclosed |
| US-10000511-B2 | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180161383-A1 | NATURAL PHARMACEUTICAL COMPOSITION FOR TREATING MENOPAUSAL MENTAL DEPRESSION AND ATYPICAL DEPRESSIVE DISORDER AND APPLICATION THEREOF | SHAANXI TIANKUI BIOMEDICINE TECH LIMITED COMPANY (CN) | 2018-06-14 | — | — | US | disclosed |
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| EP-3173411-B1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA LP (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9950062-B2 | Compounds and compositions as TLR activity modulators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-04-24 | — | — | US | disclosed |
| US-20180105561-A1 | ANALOGS OF SODIUM CHANNEL PEPTIDE TOXIN | PURDUE PHARMA LP (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180098970-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180071219-A1 | Technology for Preparation of Macromolecular Microspheres | NEXBIO, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180028449-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2018-02-01 | — | — | US | disclosed |
| US-9878991-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20180022786-A1 | NOVEL SODIUM CHANNEL BLOCKING PEPTIDES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| US-9873691-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-23 | — | — | US | disclosed |
| CN-107613965-A | For reducing the method and composition of gastric emptying | 普渡制药公司 | 2018-01-19 | — | — | CN | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-9867822-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| CN-104546669-B | Nanochannel device and correlation technique | 得克萨斯大学体系董事会 | 2018-01-05 | — | — | CN | disclosed |
| EP-3258925-A1 | METHODS AND COMPOSITIONS FOR DECREASING GASTRIC EMPTYING | Purdue Pharma LP (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170340646-A1 | Methods and Compositions for Decreasing Gastric Emptying | PURDUE PHARMA L.P. | 2017-11-30 | — | — | US | disclosed |
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| US-20170319698-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2017-11-09 | — | — | US | disclosed |
| US-20170304327-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170298027-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2017-10-19 | — | — | US | disclosed |
| EP-2709609-B1 | HETEROCYCLIC COMPOUNDS | SHIONOGI & CO (JP) | 2017-10-04 | — | — | EP | disclosed |
| US-9765029-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763955-B2 | Methods and compositions for decreasing gastric emptying | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| EP-3212167-A1 | GASTRORETENTIVE GEL FORMULATIONS | Jagotec AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| CN-107106484-A | Gastric retention gel preparation | 雅戈泰克股份公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20170226585-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2017-08-10 | — | — | US | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9718865-B2 | Sodium channel blocking peptides and the use thereof | PURDUE PHARMA L.P. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718780-B2 | Substituted pyridines as sodium channel blockers | PURDUE PHARMA L.P. | 2017-08-01 | — | — | US | disclosed |
| EP-2753606-B1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170183337-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2017-06-29 | — | — | US | disclosed |
| US-9682043-B2 | Method of preparation of mixed phase co-crystals with active agents | MEDCRYSTALFORMS, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| WO-2017100500-A1 | VESICLE CONTAINING METALLIC NANOPARTICLE AND METHOD FOR PRODUCTION THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-06-15 | — | — | WO | disclosed |
| EP-3173411-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | Purdue Pharma L.P. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20170143704-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9656968-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA L.P. | 2017-05-23 | — | — | US | disclosed |
| US-9656959-B2 | Substituted pyridines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| US-9630959-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2017-04-25 | — | — | US | disclosed |
| EP-3156053-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9624194-B2 | Heteroaryl compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-04-18 | — | — | US | disclosed |
| CN-104086540-B | Preparation method for 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | 安那迪斯药品股份有限公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-102844047-B | Immunogenic composition containing TLR active regulators | 诺华股份有限公司 | 2017-04-05 | — | — | CN | disclosed |
| US-9611222-B2 | Pyridine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20170079920-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2017-03-23 | — | — | US | disclosed |
| US-9597340-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2038286-B1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2473508-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138838-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9579299-B2 | CNS pharmaceutical compositions and methods of use | TARGIA PHARMACEUTICALS (IL) | 2017-02-28 | — | — | US | disclosed |
| EP-2723732-B1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA LP (US) | 2017-01-18 | — | — | EP | disclosed |
| US-9539253-B2 | Pyrimidine diol amides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160376658-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2016-12-29 | — | — | US | disclosed |
| US-9526824-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-12-27 | — | — | US | disclosed |
| US-9517272-B2 | Temperature dependent activation of catalytic nucleic acids for controlled active substance release | MAGFORCE AG (DE) | 2016-12-13 | — | — | US | disclosed |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2016-12-08 | — | — | US | disclosed |
| EP-2307011-B1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS INC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9492447-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2016-11-10 | — | — | US | disclosed |
| EP-2355864-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160318920-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2016-11-03 | — | — | US | disclosed |
| US-20160271127-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160264589-A1 | OPIOID KETAL COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2016-09-15 | — | — | US | disclosed |
| US-9434721-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2016-09-06 | — | — | US | disclosed |
| WO-2016134283-A1 | METHODS AND COMPOSITIONS FOR DECREASING GASTRIC EMPTYING | PURDUE PHARMA L.P. (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160244459-A1 | OPIOID KETAL COMPOUNDS AND USES THEREOF | RHODES TECHNOLOGIES (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160243129-A1 | Methods and Compositions for Decreasing Gastric Emptying | PURDUE PHARMA L.P. | 2016-08-25 | — | — | US | disclosed |
| US-20160235675-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9408919-B2 | Biodegradable polymer—bioactive moiety conjugates | POLYACTIVA PTY LTD. (AU) | 2016-08-09 | — | — | US | disclosed |
| US-20160222002-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-08-04 | — | — | US | disclosed |
| US-20160222071-A1 | ANALOGS OF SODIUM CHANNEL PEPTIDE TOXIN | PURDUE PHARMA L.P. | 2016-08-04 | — | — | US | disclosed |
| EP-3049082-A1 | TREATMENT OF BURN PAIN BY TRPV1 MODULATORS | Purdue Pharma LP (US) | 2016-08-03 | — | — | EP | disclosed |
| WO-2016118787-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20160213659-A1 | TREATMENT OF BURN PAIN BY TRPV1 MODULATORS | PURDUE PHARMA L.P. | 2016-07-28 | — | — | US | disclosed |
| EP-1807033-B1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMA (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9394293-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9388137-B2 | Quaternized amines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| CN-105744983-A | Device and method for sustained release of low water solubility therapeutic agent in solubilizer | 纳米医学系统公司 | 2016-07-06 | — | — | CN | disclosed |
| US-20160175572-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| EP-3033138-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | Nanomedical Systems Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| US-9365506-B2 | Compounds and compositions as TLR2 agonists | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-9365563-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160145210-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2016-05-26 | — | — | US | disclosed |
| US-20160139161-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2016-05-19 | — | — | US | disclosed |
| US-9340504-B2 | Pyridine and piperidine derivatives as novel sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160128949-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| WO-2016066256-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| CN-105503647-A | Preparation method of cyclopropylhydrazine hydrochloride | SUZHOU HIGHFINE BIOTECH CO LTD | 2016-04-20 | — | — | CN | disclosed |
| EP-3004115-A1 | OPIOID KETAL COMPOUNDS AND USES THEREOF | Rhodes Technologies (US) | 2016-04-13 | — | — | EP | disclosed |
| US-9308162-B2 | Biocompatible oligomer-polymer compositions | TOLMAR THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| EP-2604598-B1 | TRPV1 antagonists and uses thereof | PURDUE PHARMA LP (US) | 2016-04-06 | — | — | EP | disclosed |
| US-9301953-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2129224-B1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9279003-B2 | Analogs of sodium channel peptide toxin | PURDUE PHARMA L.P. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-9273043-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2016027259-A1 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | TARGIA PHARMACEUTICALS (IL) | 2016-02-25 | — | — | WO | disclosed |
| US-20160052911-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2016-02-25 | — | — | US | disclosed |
| EP-2655330-B1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2016-02-10 | — | — | EP | disclosed |
| US-20160024022-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2016-01-28 | — | — | US | disclosed |
| US-9233067-B2 | Silk particles for controlled and sustained delivery of compounds | AMSILK GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-20150359746-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2015-12-17 | — | — | US | disclosed |
| US-9212139-B2 | Aryl substituted indoles and their use as blockers of sodium channels | PURDUE PHARMA, L.P. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9206127-B2 | Substituted pyridines as sodium channel blockers | Purdue Pharm, L.P. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-03 | — | — | US | disclosed |
| US-9199918-B2 | Small molecule inhibitors of AGBL2 | GEORGETOWN UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150335642-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-11-26 | — | — | US | disclosed |
| US-9181185-B2 | Heteroaryl compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150315211-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| WO-2015167760-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-10-29 | — | — | US | disclosed |
| US-9168255-B2 | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | NUVO RESEARCH INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-9163008-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150290134-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | NEXBIO, INC. | 2015-10-15 | — | — | US | disclosed |
| US-9155712-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156832-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156830-B2 | Heterocyclic compounds | SHIONOGI & CO., LTD. (JP) | 2015-10-13 | — | — | US | disclosed |
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-09-17 | — | — | US | disclosed |
| US-9133131-B2 | Pyrimidine diol amides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150250789-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-09-10 | — | — | US | disclosed |
| US-20150250801-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2015-09-10 | — | — | US | disclosed |
| US-20150246174-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2912070-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | Celanese Acetate LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9120752-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150225432-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-9096743-B2 | Process for forming films, fibers, and beads from chitinous biomass | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2015-08-04 | — | — | US | disclosed |
| CN-104812777-A | Polysaccharide ester microspheres and methods and articles related thereto | CELANESE ACETATE LLC | 2015-07-29 | — | — | CN | disclosed |
| US-20150191517-A1 | NOVEL SODIUM CHANNEL BLOCKING PEPTIDES AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-07-09 | — | — | US | disclosed |
| US-9056832-B2 | Pyridine compounds and the users thereof | PURDUE PHARMA L.P. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150157578-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-9045470-B2 | Compounds and compositions as TLR activity modulators | IRM LLC (BM) | 2015-06-02 | — | — | US | disclosed |
| US-9045435-B2 | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2268618-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-05-27 | — | — | EP | disclosed |
| US-20150141434-A1 | PYRIDINE AND PIPERIDINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-21 | — | — | US | disclosed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | disclosed |
| US-20150126477-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| EP-2128125-B1 | CAFFEOYL QUINIC ACID DERIVATIVES CONTAINING NITROGEN, AND PREPARATION METHOD, PHARMACEUTICALLY COMPOSITION AND USAGE THEREOF | ZHEJIANG MED XINCHANG PHARM (CN) | 2015-05-06 | — | — | EP | disclosed |
| CN-104546669-A | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS | 2015-04-29 | — | — | CN | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9005185-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-04-14 | — | — | US | disclosed |
| WO-2015044759-A1 | TREATMENT OF BURN PAIN BY TRPV1 MODULATORS | PURDUE PHARMA L.P. (US) | 2015-04-02 | — | — | WO | disclosed |
| EP-2625169-B1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20150065492-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2015-03-05 | — | — | US | disclosed |
| CN-102504001-B | 3, 5-disubstituted and 3,5, 7-trisubstituted-3H-oxazolo and 3H-thiazolo [4,5-d ] pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS INC | 2015-02-25 | — | — | CN | disclosed |
| US-20150050713-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. | 2015-02-19 | — | — | US | disclosed |
| WO-2015023557-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| US-20150045397-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-02-12 | — | — | US | disclosed |
| US-8946243-B2 | Compounds and methods for the treatment of viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2291174-B1 | FLOWABLE COMPOSITION COMPRISING BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS INC (US) | 2015-01-28 | — | — | EP | disclosed |
| US-8937181-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2015-01-20 | — | — | US | disclosed |
| CN-102271732-B | Nanochannel devices and related methods | UNIV TEXAS | 2014-12-31 | — | — | CN | disclosed |
| CN-102015651-B | Compounds and compositions as TLR activity modulators | IRM LLC | 2014-12-31 | — | — | CN | disclosed |
| US-8921373-B2 | Compounds having TRPV1 antagonistic activity and uses thereof | SHIONOGI & CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| CN-104203220-A | Device and method for sustained release of therapeutic agent | UNIV TEXAS | 2014-12-10 | — | — | CN | disclosed |
| US-20140350056-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2014-11-27 | — | — | US | disclosed |
| US-20140348936-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-27 | — | — | US | disclosed |
| CN-101932570-B | TRPV1 antagonists and uses thereof | PURDUE PHARMA LP | 2014-11-26 | — | — | CN | disclosed |
| US-8895551-B2 | Acrylamide compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895577-B2 | Compounds and compositions as TLR activity modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-11-25 | — | — | US | disclosed |
| US-8889690-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8883758-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140329829-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20140328884-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-06 | — | — | US | disclosed |
| CN-102712636-B | Compounds and compositions as TLR activity modulators | IRM LLC | 2014-11-05 | — | — | CN | disclosed |
| US-20140323390-A1 | COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS | IRM LLC (BM) | 2014-10-30 | — | — | US | disclosed |
| US-20140315720-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315783-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2790677-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2790678-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| CN-104086540-A | Preparation method for 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC | 2014-10-08 | — | — | CN | disclosed |
| US-20140288092-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140256709-A1 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | TARGIA PHARMACEUTICALS (IL) | 2014-09-11 | — | — | US | disclosed |
| EP-2561872-B1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20140249159-A1 | HETEROCYCLIC COMPOUNDS | PURDUE PHARMA L.P. | 2014-09-04 | — | — | US | disclosed |
| US-20140249185-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2770984-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8815281-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8808703-B2 | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-08-19 | — | — | US | disclosed |
| EP-2582666-B1 | ARYL SUBSTITUTED INDOLES AND THEIR USE AS BLOCKERS OF SODIUM CHANNELS | PURDUE PHARMA LP (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20140206734-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206649-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-8784893-B2 | Polymer formulations for delivery of bioactive agents | CARBYLAN THERAPEUTICS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8765736-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765741-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140180251-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-26 | — | — | US | disclosed |
| CN-101677563-B | 5, 6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS INC | 2014-06-25 | — | — | CN | disclosed |
| US-8759362-B2 | Bicycloheteroaryl compounds and their use as TRPV1 ligands | PURDUE PHARMA L.P. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| CN-102316871-B | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS INC | 2014-06-04 | — | — | CN | disclosed |
| US-20140142077-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | LABORATORIES BESINS INTERNATIONAL, SAS (FR) | 2014-05-22 | — | — | US | disclosed |
| US-20140142112-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8729070-B2 | CNS pharmaceutical compositions and methods of use | TARGIA PHARMACEUTICALS (IL) | 2014-05-20 | — | — | US | disclosed |
| US-20140134150-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | ANSUN BIOPHARMA, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8722725-B2 | Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2014-05-13 | — | — | US | disclosed |
| WO-2014066463-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-05-01 | — | — | WO | disclosed |
| EP-2723732-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | Purdue Pharma LP (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20140113826-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-04-24 | — | — | US | disclosed |
| US-8703962-B2 | Monocyclic compounds and their use as TRPV1 ligands | PURDUE PHARMA L.P. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8697361-B2 | Serotonin transporter gene and treatment of alcoholism | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140099696-A1 | Technology for the Preparation of Microparticles | ANSUN BIOPHARMA, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| CN-102428069-B | Acrylamide compounds and the use thereof | SHIONOGI & CO | 2014-04-02 | — | — | CN | disclosed |
| EP-2709609-A1 | HETEROCYCLIC COMPOUNDS | Shionogi & Co., Ltd. (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8680118-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-03-25 | — | — | US | disclosed |
| WO-2014031398-A1 | BIOMEDICAL DEVICES COMPRISING MOLDED POLYETHYLENE COMPONENTS | TICONA LLC (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20140052264-A1 | Porous, Stabilized Craniomaxillofacial Implants and Methods and Kits Relating Thereto | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051771-A1 | Biomedical Devices Comprising Molded Polyethylene Components | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140046018-A1 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | POLYACTIVA PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | disclosed |
| EP-1824482-B1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20140031346-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2014016673-A1 | SODIUM CHANNEL BLOCKING PEPTIDES AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014018913-A2 | SANTACRUZAMATE A COMPOSITIONS AND ANALOGS AND METHODS OF USE | UNIVERSITY OF CONNECTICUT (US) | 2014-01-30 | — | — | WO | disclosed |
| US-8637548-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8632510-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-01-21 | — | — | US | disclosed |
| US-8623419-B2 | Technology for preparation of macromolecular microspheres | ANSUN BIOPHARMA, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20140005212-A1 | Substituted Pyridines as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2678318-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| CN-103492369-A | Cannabinoid receptor modulators | ARENA PHARM INC | 2014-01-01 | — | — | CN | disclosed |
| US-20130345211-A1 | Pyridine Compounds as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2142529-B1 | TRPV1 ANTAGONISTS AND USES THEREOF | PURDUE PHARMA LP (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2676956-A1 | Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof | Purdue Pharma L.P. (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | NUVO RESEARCH INC. (CA) | 2013-12-19 | — | — | US | disclosed |
| US-20130338170-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130331328-A1 | SMALL MOLECULE INHIBITORS OF AGBL2 | GEORGETOWN UNIVERSITY (US) | 2013-12-12 | — | — | US | disclosed |
| US-8604037-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8591941-B2 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8586578-B2 | Deuterated 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130296247-A1 | Analogs of Sodium Channel Peptide Toxin | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | disclosed |
| US-8575199-B2 | Formula (IA″) compounds comprising (piperidin-4-yl)pyridine or (1,2,3,6-tetrahydropyridin-4-4yl) as TRPV1 antagonists | PURDUE PHARMA L.P. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130289044-A1 | Quinazoline Compounds as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2013-10-31 | — | — | US | disclosed |
| EP-2459216-B1 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| EP-2655330-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | Purdue Pharma LP (US) | 2013-10-30 | — | — | EP | disclosed |
| CN-101605457-B | P-toluene sulfonic acid salt of 5-amino-3-(2'-o-acetyl-3'-deoxy-ss-d-ribofuranosyl)-3h-thiazole [4, 5-d] pyrimidine-2-one and methods for preparation | ANADYS PHARMACEUTICALS INC | 2013-10-30 | — | — | CN | disclosed |
| EP-2414332-B1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-8563732-B2 | Oxyimino compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130259831-A1 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8546602-B2 | 5,6-D hydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546417-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546388-B2 | Heterocyclic TRPV1 receptor ligands | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-26 | — | — | US | disclosed |
| US-20130240483-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013136170-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-09-19 | — | — | WO | disclosed |
| EP-2331522-B1 | TETRAHYDROPYRIDINYL AND DIHYDROPYRROLYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8536177-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8535655-B2 | Biodegradable polymer—bioactive moiety conjugates | POLYACTIVA PTY LTD. (AU) | 2013-09-17 | — | — | US | disclosed |
| CN-103271083-A | Multi-functional ionic liquid compositions | UNIV ALABAMA | 2013-09-04 | — | — | CN | disclosed |
| US-8518934-B2 | Oxycarbamoyl compounds and the use thereof | SHONOGI & CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2384768-B1 | Phenylpropionamide compounds and the use thereof | PURDUE PHARMA LP (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8513304-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-08-20 | — | — | US | disclosed |
| EP-2625169-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | Purdue Pharma L.P. (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2616441-A2 | PYRIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8481743-B2 | Phenylpropionamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8480637-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-09 | — | — | US | disclosed |
| US-8476277-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2013090893-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090891-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| EP-2604599-A1 | TRPV1 antagonists and uses thereof | Purdue Pharma LP (US) | 2013-06-19 | — | — | EP | disclosed |
| EP-2604598-A1 | TRPV1 antagonists and uses thereof | Purdue Pharma L.P. (US) | 2013-06-19 | — | — | EP | disclosed |
| CN-103168033-A | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA LP | 2013-06-19 | — | — | CN | disclosed |
| US-8466167-B2 | Compounds and compositions as TLR activity modulators | IRM LLC (BM) | 2013-06-18 | — | — | US | disclosed |
| US-20130150377-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHIONOGI & CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| CN-101326275-B | Multifunctional ionic liquid composition | UNIV ALABAMA | 2013-06-05 | — | — | CN | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130131628-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013072758-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-23 | — | — | WO | disclosed |
| EP-2593434-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | Purdue Pharma LP (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | PURDUE PHARMA L.P. | 2013-05-16 | — | — | US | disclosed |
| EP-2091936-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA LP (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2013064883-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064884-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109762-A1 | SILK PARTICLES FOR CONTROLLED AND SUSTAINED DELIVERY OF COMPOUNDS | AMSILK GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| WO-2013063004-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-2585446-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | Shionogi&Co., Ltd. (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102545-A1 | TEMPERATURE DEPENDENT ACTIVATION OF CATALYTIC NUCLEIC ACIDS FOR CONTROLLED ACTIVE SUBSTANCE RELEASE | MAGFORCE AG | 2013-04-25 | — | — | US | disclosed |
| EP-2164325-B1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-04-24 | — | — | EP | disclosed |
| EP-2255184-B1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | Univ Virginia Patent Found (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2582666-A2 | ARYL SUBSTITUTED INDOLES AND THEIR USE AS BLOCKERS OF SODIUM CHANNELS | Purdue Pharma L.P. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8414914-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20130079404-A1 | TOPICAL FORMULATION | NUVO RESEARCH INC. (CA) | 2013-03-28 | — | — | US | disclosed |
| US-8399486-B2 | Benzenesulfonyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20130065861-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2013-03-14 | — | — | US | disclosed |
| WO-2012176061-A9 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013030665-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-8389549-B2 | Substituted pyridines useful for treating pain | PURDUE PHARMA L.P. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2561872-A1 | 3, 5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof | Anadys Pharmaceuticals, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | disclosed |
| WO-2013021276-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-2346820-B1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-02-13 | — | — | EP | disclosed |
| EP-2556830-A1 | Combined effects of topiramate, ondansetron and naltrexone on alcohol consumption | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20130035304-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2013-02-07 | — | — | US | disclosed |
| EP-2549990-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2013-01-30 | — | — | EP | disclosed |
| US-8357723-B2 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited and Apparao Satyam (IN) | 2013-01-22 | — | — | US | disclosed |
| US-8354455-B2 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited and Apparao Satyam (IN) | 2013-01-15 | — | — | US | disclosed |
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20130012541-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2013-01-10 | — | — | US | disclosed |
| EP-1927858-B1 | Conformationally constrained peptides that bind the ORL-1 receptor | EURO CELTIQUE SA (LU) | 2013-01-09 | — | — | EP | disclosed |
| US-8349842-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349901-B2 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited and Apparao Satyam (IN) | 2013-01-08 | — | — | US | disclosed |
| CN-102858344-A | Deuterated 5,6-dihydro-1h-pyridin-2-one Compounds | ANADYS PHARMACEUTICALS INC | 2013-01-02 | — | — | CN | disclosed |
| US-8343962-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| WO-2012176061-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-12-27 | — | — | WO | disclosed |
| CN-102844047-A | Immunogenic compositions including tlr activity modulators | NOVARTIS AG | 2012-12-26 | — | — | CN | disclosed |
| US-20120321590-A1 | BRIDGED POLYCYCLIC COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120308644-A1 | Compositions for mucosal delivery of agents | ARCHIMEDES LABORATORIES, INC. | 2012-12-06 | — | — | US | disclosed |
| EP-2528893-A2 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATIING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8324249-B2 | Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120302744-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302592-A1 | TOPIRAMATE PLUS NALTREXONE FOR THE TREATMENT OF ADDICTIVE DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012158271-A1 | BRIDGED POLYCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158844-A1 | HETEROCYCLIC COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 2012-11-22 | — | — | WO | disclosed |
| EP-1758916-B1 | 3-BETA-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-8314077-B2 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120283251-A1 | DEUTERATED 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120269881-A9 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| CN-102740693-A | Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity | UNITED PARAGON ASSOCIATES INC | 2012-10-17 | — | — | CN | disclosed |
| EP-2506837-A2 | SPIDER SILK PARTICLES FOR CONTROLLED AND SUSTAINED DELIVERY OF COMPOUNDS | Amsilk GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| CN-102712636-A | Compounds and compositions as TLR activity modulators | IRM LLC | 2012-10-03 | — | — | CN | disclosed |
| US-20120245134-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120237546-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2012-09-20 | — | — | US | disclosed |
| CN-101516192-B | Prodrugs of 5-amino-3- (3' -deoxy-beta-D-ribofuranosyl) -thiazolo [4,5-D ] pyrimidine-2, 7-dione | ANADYS PHARMACEUTICALS INC | 2012-09-19 | — | — | CN | disclosed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| EP-2493476-A1 | DEUTERATED 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | Anadys Pharmaceuticals, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220962-A1 | TRANSDERMAL AND TOPICAL ADMINISTRATION OF VITAMINS USING BASIC PERMEATION ENHANCERS | TECHNOLOGY RECOVERY SYSTEMS, LLC (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012116277-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116278-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116279-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252323-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2012112567-A1 | SMALL MOLECULE INHIBITORS OF AGBL2 | GEORGETOWN UNIVERSITY (US) | 2012-08-23 | — | — | WO | disclosed |
| US-8247442-B2 | Benzenesulfonamide compounds and their use | PURDUE PHARMA L.P. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1951718-B9 | 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF | PURDUE PHARMA LP (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-1768647-B1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT | VIRUN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8236948-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120190743-A1 | COMPOUNDS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH NEUROKININ 2 RECEPTOR ACTIVITY | UNITED PARAGON ASSOCIATES INC. (CA) | 2012-07-26 | — | — | US | disclosed |
| EP-2479173-A1 | Therapeutic agents useful for treating pain | Purdue Pharma LP (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8227467-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-07-24 | — | — | US | disclosed |
| CN-102584649-A | Pyrro[1,2-b]pyridazinone compounds | ANADYS PHARMACEUTICALS INC | 2012-07-18 | — | — | CN | disclosed |
| US-8222404-B2 | [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120177570-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-07-12 | — | — | US | disclosed |
| EP-1628652-B1 | COMBINATION OF THE ANALEPTIC MODAFINIL AND AN ANTIDEPRESSANT FOR THE TREATMENT OF DEPRESSION | CEPHALON INC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2076132-B1 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-BETA -D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D]PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | ANADYS PHARMACEUTICALS INC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2473508-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2012-07-11 | — | — | EP | disclosed |
| EP-2473038-A1 | COMPOUNDS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH NEUROKININ 2 RECEPTOR ACTIVITY | United Paragon Associates Inc. (CA) | 2012-07-11 | — | — | EP | disclosed |
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120165762-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| WO-2012085650-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2012-06-28 | — | — | WO | disclosed |
| CN-102504001-A | 3, 5-disubstituted and 3,5, 7-trisubstituted-3H-oxazolo and 3H-thiazolo [4,5-d ] pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS INC | 2012-06-20 | — | — | CN | disclosed |
| EP-2079485-B1 | PHENYLPROPIONAMIDE COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120141590-A1 | Technology for the Preparation of Microparticles | MALAKHOV MICHAEL (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2459216-A2 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | Novartis AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193342-B2 | Method for preparing furanose compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120130068-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8178560-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120115729-A1 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120116062-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | ANSUN BIOPHARMA, INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120115149-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| CN-102428069-A | Acrylamide compound and use thereof | SHIONOGI & CO | 2012-04-25 | — | — | CN | disclosed |
| US-20120095443-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8158152-B2 | Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets | SCIDOSE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| WO-2012046132-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-2437734-A2 | ORALLY DISINTEGRATING DOSAGE FORMS CONTAINING TASTE-MASKED ACTIVE INGREDIENTS | BASF SE (DE) | 2012-04-11 | — | — | EP | disclosed |
| US-8153159-B2 | Upon administration, unit dosage form releases a first effective amount, followed by a time interval during which substantially no modafinil compound is released, after which a second amount is released; core particle surrounded by enteric and water insoluble polymers; drug delivery | CEPHALON, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2012035421-A2 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065180-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120058981-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-03-08 | — | — | US | disclosed |
| EP-2425013-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | University Of Virginia Patent Foundation (US) | 2012-03-07 | — | — | EP | disclosed |
| US-8129368-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129388-B2 | Therapeutic agents useful for treating pain | Purde Pharma L.P. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-1951718-B1 | 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF | PURDUE PHARMA LP (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2419091-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2012-02-22 | — | — | EP | disclosed |
| CN-101501039-B | Pyrrolo [1,2-b ] pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-22 | — | — | CN | disclosed |
| EP-2414332-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | Shionogi & Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-8101800-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20120015954-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007836-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA .LP. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-8097613-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097718-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| WO-2012004664-A2 | ANALOGS OF SODIUM CHANNEL PEPTIDE TOXIN | PURDUE PHARMA L.P. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20120004217-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011162409-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011158108-A2 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20110305768-A1 | QUICK-DISSOLVING ORAL THIN FILM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306582-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110288100-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110281885-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281876-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8058292-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110274695-A1 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | PIRAMAL LIFE SCIENCES LIMITED | 2011-11-10 | — | — | US | disclosed |
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2384768-A1 | Phenylpropionamide compounds and the use thereof | Purdue Pharma LP (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110269709-A1 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | PIRAMAL LIFE SCIENCES LIMITED | 2011-11-03 | — | — | US | disclosed |
| US-20110269722-A1 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | Piramal Life Science Limited | 2011-11-03 | — | — | US | disclosed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| US-8034802-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110243884-A1 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | THE BIONICS INSTITUTE OF AUSTRALIA (AU) | 2011-10-06 | — | — | US | disclosed |
| US-8030310-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2011-10-04 | — | — | US | disclosed |
| WO-2011119759-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2011-09-29 | — | — | WO | disclosed |
| US-8026254-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2011-09-27 | — | — | US | disclosed |
| EP-1942106-B1 | Therapeutic agents useful for treating pain | EURO CELTIQUE SA (LU) | 2011-09-14 | — | — | EP | disclosed |
| US-8008300-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2355864-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2355853-A1 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | The Bionic Ear Institute (AU) | 2011-08-17 | — | — | EP | disclosed |
| US-7994177-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| WO-2011094708-A2 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATIING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110184003-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 2011-07-28 | — | — | US | disclosed |
| EP-2346820-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | Shionogi & Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110172447-A1 | METHOD FOR PREPARING FURANOSE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-7976871-B2 | Modified release composition of highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-07-12 | — | — | US | disclosed |
| US-20110166344-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2340271-A1 | POLYMER-BIOACTIVE AGENT CONJUGATES | The Bionic Ear Institute (AU) | 2011-07-06 | — | — | EP | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| US-20110152324-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-06-23 | — | — | US | disclosed |
| US-7964606-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2331522-A2 | TETRAHYDROPYRIDINYL AND DIHYDROPYRROLYL COMPOUNDS AND THE USE THEREOF | Purdue Pharma LP (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110136833-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHINOGI & CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| WO-2011063990-A2 | SILK PARTICLES FOR CONTROLLED AND SUSTAINED DELIVERY OF COMPOUNDS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2011-06-03 | — | — | WO | disclosed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20110117184-A1 | Compositions for mucosal delivery of agents | VIRUN, INC. | 2011-05-19 | — | — | US | disclosed |
| US-7943759-B2 | 3-β-D-ribofuranosylthiazolo[4-5-d]pyrimidine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20110112159-A1 | SEROTONIN TRANSPORTER GENE AND TREAMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011056647-A1 | DEUTERATED 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057148-A1 | COMPOUNDS AND COMPOSITIONS AS TLR-7 ACTIVITY MODULATORS | IRM LLC (BM) | 2011-05-12 | — | — | WO | disclosed |
| US-7939670-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939524-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2011049677-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-28 | — | — | WO | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
| US-20110097384-A1 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098281-A9 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7932294-B2 | Prodrugs containing novel bio-cleavable linkers | APPARAO SATYAM (IN) | 2011-04-26 | — | — | US | disclosed |
| US-7928085-B2 | P-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazole[4,5-d]pyrimidine-2-one and methods for preparation | ANADYS PHARMACEUTICALS, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2307011-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| CN-102016571-A | Serotonin transporter gene and treatment of alcoholism | UNIV VIRGINIA | 2011-04-13 | — | — | CN | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
| US-20110082152-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110071192-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2298764-A1 | 4-Oxadiazolyl-piperidine compounds and use thereof | Purdue Pharma LP (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298765-A1 | 4-Oxadiazolyl-piperidine compounds and use thereof | Purdue Pharma LP (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110065628-A1 | Medication Combinations for the Treatment of Alcoholism and Drug Addiction | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-03-17 | — | — | US | disclosed |
| EP-1648878-B9 | PIPERIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EURO CELTIQUE SA (LU) | 2011-03-16 | — | — | EP | disclosed |
| US-7906140-B2 | Compositions for mucosal delivery of agents | VIRUN, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| WO-2011027222-A2 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011029099-A1 | COMPOUNDS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH NEUROKININ 2 RECEPTOR ACTIVITY | UNITED PARAGON ASSOCIATES INC. (CA) | 2011-03-10 | — | — | WO | disclosed |
| EP-2291174-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | Tolmar Therapeutics, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20110053893-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110054038-A1 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | TARGIA PHARMACEUTICALS (IL) | 2011-03-03 | — | — | US | disclosed |
| EP-2040712-B1 | CARBONATE AND CARBAMATE PRODRUGS OF THIAZOLO [4,5-D] PYRIMIDINES | ANADYS PHARMACEUTICALS INC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20110033540-A1 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | CARBYLAN THERAPEUTICS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110028460-A1 | TOPICAL FORMULATION | FQUBED, INC. | 2011-02-03 | — | — | US | disclosed |
| EP-2034834-B1 | PRODRUGS OF 5-AMINO-3-(3'-DEOXY-BETA-D-RIBOFURANOSYL)-THIAZOLO[4,5-D]PYRIMIDIN-2,7-DIONE | ANADYS PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2017276-B1 | Phenyl-carboxamide compounds useful for treating pain | EURO CELTIQUE SA (LU) | 2011-01-19 | — | — | EP | disclosed |
| EP-2274311-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-2275420-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009418-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2268618-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269657-A2 | Prodrugs containing novel bio-cleavable linkers | Piramal Life Sciences Limited (IN) | 2011-01-05 | — | — | EP | disclosed |
| CN-101024614-B | Analysis method for use in gas-phase chromatogram of esterization, cycle compounding process in production of cyclo-ammonium | UNIV INNER MONGOLIA NORMAL | 2011-01-05 | — | — | CN | disclosed |
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2266622-A2 | Prodrugs containing novel bio-cleavable linkers | Piramal Life Sciences Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266623-A2 | Prodrugs containing novel bio-cleavable linkers | Piramal Life Sciences Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266625-A2 | Prodrugs Containing Novel Bio-Cleavable Linkers | Piramal Life Sciences Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| CN-101932570-A | The TRPV1 antagonist with and uses thereof | SHIONOGI & CO | 2010-12-29 | — | — | CN | disclosed |
| US-7858637-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | AVERETT DEVRON R | 2010-12-28 | — | — | US | disclosed |
| US-7855210-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100317670-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100311792-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2010-12-09 | — | — | US | disclosed |
| WO-2010141470-A2 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139654-A2 | ORALLY DISINTEGRATING DOSAGE FORMS CONTAINING TASTE-MASKED ACTIVE INGREDIENTS | BASF SE (DE) | 2010-12-09 | — | — | WO | disclosed |
| EP-2255184-A2 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | University Of Virginia Patent Foundation (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-2254420-A2 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | Targia Pharmaceuticals (IL) | 2010-12-01 | — | — | EP | disclosed |
| US-7842838-B2 | Pyrro[1,2-b]pyridazinone intermediates | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7834009-B2 | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2010126603-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010120817-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-21 | — | — | WO | disclosed |
| CN-101863877-A | Be used for the treatment of the treatment of pain agent | EURO CELTIQUE SA | 2010-10-20 | — | — | CN | disclosed |
| US-20100261667-A1 | 3-ß-D-RIBOFURANOSYLTHIAZOLO[4-5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256169-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2010114181-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-07 | — | — | WO | disclosed |
| US-20100240675-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240703-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2010-09-23 | — | — | US | disclosed |
| US-7799807-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799786-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100234426-A1 | Phenylpropionamide Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100210686-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-08-19 | — | — | US | disclosed |
| US-7776861-B2 | Cycloheteroalkenyl compounds used as analgesics and for treating incontinence, inflammatory bowel disease, Parkinson's disease, amyotrophic lateral sclerosis, dementia, epilepsy, retinopathy, pruritus, psychoses, Huntington's disease, headaches, vomiting, dyskinesia or as anxiolytics and antidepressants | PURDUE PHARMA L.P. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7772254-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772206-B2 | Methods and compositions for the treatment of autoimmune disorders using clofarabine | GENZYME CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| CN-101148448-B | Method for preparing N2-quinoline substituted purine derivative | ZHEJIANG MEDICAL CO LTD XINCHANG PHARMACEUTICAL PLANT | 2010-08-04 | — | — | CN | disclosed |
| US-7767699-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7754723-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P., USA | 2010-07-13 | — | — | US | disclosed |
| WO-2010078300-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-1499888-B1 | CONFORMATIONALLY CONSTRAINED PEPTIDES THAT BIND THE ORL-1 RECEPTOR | EURO CELTIQUE SA (LU) | 2010-07-07 | — | — | EP | disclosed |
| US-20100166874-A1 | Technology for Preparation of Macromolecular Microspheres | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-01 | — | — | US | disclosed |
| US-7745415-B2 | 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| CN-1835751-B | Therapeutic agent for treating pain | EURO CELTIQUE SA | 2010-06-23 | — | — | CN | disclosed |
| WO-2010040188-A9 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | THE BIONIC EAR INSTITUTE (AU) | 2010-06-17 | — | — | WO | disclosed |
| US-20100152699-A1 | Nanochanneled Device and Related Methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-17 | — | — | US | disclosed |
| US-7737148-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100144828-A1 | CAFFEOYLQUINIC ACID DERIVATIVES CONTAINING NITROGEN, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USAGE THEREOF | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICA (CN) | 2010-06-10 | — | — | US | disclosed |
| US-20100137306-A1 | HETEROCYCLIC TRPV1 RECEPTOR LIGANDS | PURDUE PHARMA L.P. | 2010-06-03 | — | — | US | disclosed |
| US-20100130499-A1 | BICYCLOHETEROARYL COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS | PURDUE PHARMA L.P. | 2010-05-27 | — | — | US | disclosed |
| US-20100130552-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. | 2010-05-27 | — | — | US | disclosed |
| WO-2010056986-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100119481-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120862-A1 | MONOCYCLIC COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS | PURDUE PHARMA L.P. | 2010-05-13 | — | — | US | disclosed |
| EP-1810970-B1 | Therapeutic piperazine compounds | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | disclosed |
| US-7709448-B2 | Prodrugs of 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione | ANADYS PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1667694-B1 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | ANADYS PHARMACEUTICALS INC (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-1472225-B1 | 2-PIPERAZINE-PYRIDINES USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2010-04-28 | — | — | EP | disclosed |
| EP-2176301-A1 | AQUEOUS POLYMER DISPERSION BASED ON N,N-DIETHYLAMINOETHYL METHACRYLATE, ITS PREPARATION AND USE | BASF SE (DE) | 2010-04-21 | — | — | EP | disclosed |
| WO-2010040188-A1 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | THE BIONIC EAR INSTITUTE (AU) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010040187-A1 | POLYMER-BIOACTIVE AGENT CONJUGATES | THE BIONIC EAR INSTITUTE (AU) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042830-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| EP-2173327-A2 | TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES | Nexbio, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7696207-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696208-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2172468-A1 | Benzimidazolone compounds | EURO-CELTIQUE S.A. (LU) | 2010-04-07 | — | — | EP | disclosed |
| US-7687518-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20100076006-A1 | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2164325-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | Shionogi&Co., Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| EP-2164326-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | Euro-Celtique, S.A. (LU) | 2010-03-24 | — | — | EP | disclosed |
| CN-101677563-A | 5, 6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS INC | 2010-03-24 | — | — | CN | disclosed |
| US-7683063-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20100069437-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| CN-101663028-A | Combined effect of topiramate and ondansetron on alcohol consumption | UNIV VIRGINIA | 2010-03-03 | — | — | CN | disclosed |
| CN-101657444-A | Derivatives and analogs of chroman as functionally selective alpha2C adrenoreceptor agonists | SCHERING CORP US | 2010-02-24 | — | — | CN | disclosed |
| US-20100041689-A1 | Combined Effects of Topiramate and Ondansetron on Alcohol Consumption | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-02-18 | — | — | US | disclosed |
| CN-101648941-A | 4-tetrazolyl-4phenylpiperidine derivatives for treating pain | EURO CELTIQUE SA | 2010-02-17 | — | — | CN | disclosed |
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2010014257-A2 | TETRAHYDROPYRIDINYL AND DIHYDROPYRROLYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | disclosed |
| EP-1975164-B1 | Octahydrobenzimidazolone compounds as analgetics | EURO CELTIQUE SA (LU) | 2010-01-27 | — | — | EP | disclosed |
| EP-1648880-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2010-01-20 | — | — | EP | disclosed |
| EP-2142529-A2 | TRPV1 ANTAGONISTS AND USES THEREOF | Purdue Pharma LP (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20100004254-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010002418-A2 | QUICK-DISSOLVING ORAL THIN FILM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20090318398-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | UNIMED PHARMACEUTICALS, LLC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090317453-A1 | TRANSDERMAL AND TOPICAL ADMINISTRATION OF DRUGS USING BASIC PERMEATION ENHANCERS | DERMATRENDS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318520-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS DRIVE (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009155139-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009152166-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151152-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-12-17 | — | — | WO | disclosed |
| CN-101605457-A | P-toluenesulfonate of 5-amino-3-(2'-0-acetyl-3'-deoxy-beta-D-ribofuranosyl)-3H-thiazole [4,5-D] pyrimidin-2-one and method of preparation | ANADYS PHARMACEUTICALS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| US-20090306136-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2009-12-10 | — | — | US | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009148581-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | QLT USA, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-2129224-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | Anadys Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| CN-100567288-C | 4-tetrazolyl-4-phenylpiperidine derivatives for the treatment of pain | EURO CELTIQUE SA (LU) | 2009-12-09 | — | — | CN | disclosed |
| US-20090297478-A1 | Methods and Compositions for the Treatment of Lupus Using Clofarabine | WOOD CHRISTOPHER B | 2009-12-03 | — | — | US | disclosed |
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2124909-A2 | COMBINED EFFECTS OF TOPIRAMATE AND ONDANSETRON ON ALCOHOL CONSUMPTION | University Of Virginia Patent Foundation (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2128125-A1 | CAFFEOYL QUINIC ACID DERIVATIVES CONTAINING NITROGEN, AND PREPARATION METHOD, PHARMACEUTICALLY COMPOSITION AND USAGE THEREOF | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009142827-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-2117513-A2 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | Carbylan Biosurgery, Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-1670447-B1 | MODAFINIL MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS | CEPHALON INC (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-1598338-B9 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-11-18 | — | — | EP | disclosed |
| CN-100560584-C | Benzazoles bridged piperazine derivatives with VR1 antagonistic activity | EURO CELTIQUE SA (LU) | 2009-11-18 | — | — | CN | disclosed |
| US-20090253727-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090239910-A1 | Benzenesulfonamide Compounds and Their Use | EURO-CELTIQUE S.A. (LU) | 2009-09-24 | — | — | US | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009108837-A2 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-09-03 | — | — | WO | disclosed |
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582754-B2 | For treating hepatitis C virus infections; polymerase inhibitors | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582635-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. | 2009-09-01 | — | — | US | disclosed |
| WO-2009104080-A2 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | TARGIA PHARMACEUTICALS (IL) | 2009-08-27 | — | — | WO | disclosed |
| EP-1824482-A4 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-2091936-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | Purdue Pharma LP (US) | 2009-08-26 | — | — | EP | disclosed |
| CN-101516192-A | Prodrugs of 5-amino-3- (3' -deoxy-beta-D-ribofuranosyl) -thiazolo [4, 5-D ] pyrimidine-2, 7-dione | ANADYS PHARMACEUTICALS INC (US) | 2009-08-26 | — | — | CN | disclosed |
| US-7576068-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1385514-B9 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2009-08-12 | — | — | EP | disclosed |
| US-7572812-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P., USA | 2009-08-11 | — | — | US | disclosed |
| US-20090197849-A1 | TRANSDERMAL AND TOPICAL ADMINISTRATION OF DRUGS USING BASIC PERMEATION ENHANCERS | DERMATRENDS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197826-A1 | P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]pyrimidine-2-one and Methods for Preparation | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| CN-101501039-A | Pyrrolo [1, 2-b ] pyridazinone compounds | ANADYS PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-2079485-A2 | PHENYLPROPIONAMIDE COMPOUNDS AND THE USE THEREOF | Purdue Pharma LP (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-2080757-A1 | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain | EURO-CELTIQUE S.A. (LU) | 2009-07-22 | — | — | EP | disclosed |
| US-7563809-B2 | Nociceptin analogs | PURDUE PHARMA, L.P. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7560544-B2 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1664016-B9 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2009-07-08 | — | — | EP | disclosed |
| EP-2076132-A1 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-BETA -D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D]PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | Anadys Pharmaceuticals, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090170868-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-2075011-A2 | Prodrugs Containing Bio-Cleavable Linkers | Piramal Life Sciences Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| EP-1598339-B1 | 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-06-24 | — | — | EP | disclosed |
| US-20090155211-A1 | multiple sclerosis; side effect reduction | WOOD CHRISTOPHER B | 2009-06-18 | — | — | US | disclosed |
| US-20090156640-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE S.A. | 2009-06-18 | — | — | US | disclosed |
| EP-2067776-A1 | Piperidine compounds and pharmaceutical compositions containing them | EURO-CELTIQUE S.A. (LU) | 2009-06-10 | — | — | EP | disclosed |
| EP-1867644-B1 | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain | EURO CELTIQUE SA (LU) | 2009-05-20 | — | — | EP | disclosed |
| EP-2060260-A1 | Therapeutic agents useful for treating pain | Euro-Celtique S.A. (LU) | 2009-05-20 | — | — | EP | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
| EP-1648878-B1 | PIPERIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EURO CELTIQUE SA (LU) | 2009-05-06 | — | — | EP | disclosed |
| US-7528115-B2 | Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines | ANADYS PHARMACEUTICALS, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105473-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| EP-2050450-A1 | 1-Piperidine-2-cyanoimino-1,3-dihydro-2H-benzimidazole derivatives as nociceptin analogs with ORL1 modulating activity for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2009-04-22 | — | — | EP | disclosed |
| US-20090098207-A1 | Technology for the Preparation of Microparticles | NEXBIO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009040659-A2 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (DE) | 2009-04-02 | — | — | WO | disclosed |
| EP-2040712-A2 | CARBONATE AND CARBAMATE PRODRUGS OF THIAZOLO [4,5-D] PYRIMIDINES | Anadys Pharmaceuticals, Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2009038605-A2 | FLEXIBLE, POLYVALENT ANTIVIRAL DENDRIDIC CONJUGATES FOR THE TREATMENT OF HIV/AIDS AND ENVELOPED VIRAL INFECTION | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-03-26 | — | — | WO | disclosed |
| EP-1551386-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LUPUS USING CLOFARABINE | BIOENVISION INC (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-2038286-A1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | Anadys Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-2034834-A2 | PRODRUGS OF 5-AMINO-3-(3'-DEOXY-BETA -D-RIBOFURANOSYL)-THIAZOLO[4,5-d]PYRIMIDIN-2,7-DIONE | Anadys Pharmaceuticals, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009032244-A1 | METHOD FOR THE TREATMENT OF HIV/AIDS INFECTION USING ACYCLOVIR IN IDENTIFIED SUBJECTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-2033644-A1 | Spiroindene and spiroindane compounds | EURO-CELTIQUE S.A. (LU) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033951-A2 | 2-Piperazine-pyridines useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009029308-A1 | MEDICATION COMBINATIONS FOR THE TREATMENT OF ALCOHOLISM AND DRUG ADDICTION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062263-A1 | treating hepatitis C virus infections; inhibitor of HCV NS5B polymerase; N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-5-(3-methyl-butyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-1,1-dioxo-1,4-dihydro-1(lambda 6)-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide; coadministering with additional therapeutic agent | ANADYS PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| EP-1598340-B1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-BENZOXAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-03-04 | — | — | EP | disclosed |
| US-7495109-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1598338-B1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-02-18 | — | — | EP | disclosed |
| EP-1641775-B1 | 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2009-02-18 | — | — | EP | disclosed |
| EP-1727801-B1 | PIPERAZINES USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2009-02-18 | — | — | EP | disclosed |
| US-20090042902-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2009016258-A1 | AQUEOUS POLYMER DISPERSION BASED ON N,N-DIETHYLAMINOETHYL METHACRYLATE, ITS PREPARATION AND USE | BASF SE (DE) | 2009-02-05 | — | — | WO | disclosed |
| CN-100457735-C | Therapeutic agents useful for treating pain | EURO CELTIQUE SA (LU) | 2009-02-04 | — | — | CN | disclosed |
| WO-2009015286-A2 | TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES | NEXBIO, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-2017276-A1 | Phenyl-carboxamide compounds useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2009-01-21 | — | — | EP | disclosed |
| EP-1509523-B1 | TRIAZASPIRO COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | EURO CELTIQUE SA (LU) | 2009-01-21 | — | — | EP | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| US-20080319020-A1 | 4-Oxadiazolyl-Piperidine Compounds and Use Thereof | PURDUE PHARMA L.P. | 2008-12-25 | — | — | US | disclosed |
| US-20080319092-A1 | Transdermal Drug Delivery Formulation | NUVO RESEARCH INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| CN-101326275-A | Multifunctional ionic liquid composition | UNIV ALABAMA (US) | 2008-12-17 | — | — | CN | disclosed |
| WO-2008150470-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
| US-7462611-B2 | inhibitor of HCV NS5B polymerase; to treat infections caused by hepatitis C virus; 3-(1,1-Dioxo-1,4-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-4-hydroxy-1-(3-methyl-butyl)-pyrrolo[1,2-b]pyridazin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1997818-A2 | Quinolinone derivatives and their use to treat pain | EURO-CELTIQUE S.A. (LU) | 2008-12-03 | — | — | EP | disclosed |
| US-20080292588-A1 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008144500-A2 | 1-METHYL-BENZO[1,2,4]THIADIAZINE, 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| CN-101312964-A | 4-oxadiazolyl piperidine compound and use thereof | PURDUE PHARMA LP (US) | 2008-11-26 | — | — | CN | disclosed |
| WO-2008140549-A1 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-β-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008133973-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132600-A2 | TRPV1 ANTAGONISTS AND USES THEREOF | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275032-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| EP-1862458-B1 | Therapeutic agents useful for treating pain | EURO CELTIQUE SA (LU) | 2008-11-05 | — | — | EP | disclosed |
| EP-1385514-B1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2008-11-05 | — | — | EP | disclosed |
| EP-1987009-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2008-11-05 | — | — | EP | disclosed |
| EP-1664016-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2008-10-29 | — | — | EP | disclosed |
| EP-1648879-B1 | HETEROARYL-TETRAHYDROPYRIDYL COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | EURO CELTIQUE SA (LU) | 2008-10-22 | — | — | EP | disclosed |
| EP-1981483-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | Nexbio, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008124450-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080255063-A1 | 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008124118-A1 | BENZENESULFONYL COMPOUNDS AND THE USE THEROF | PURDUE PHARMA L.P. (DE) | 2008-10-16 | — | — | WO | disclosed |
| EP-1379246-B1 | NOCICEPTIN ANALOGS | EURO CELTIQUE SA (LU) | 2008-10-08 | — | — | EP | disclosed |
| EP-1975164-A2 | Octahydrobenzimidazolone compounds as analgetics | EURO-CELTIQUE S.A. (LU) | 2008-10-01 | — | — | EP | disclosed |
| US-20080227774-A1 | 5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-7425552-B2 | Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction | ANADYS PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080214827-A1 | For severe and chronic pain; 1-(1-Cyclooctyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-ylidene-cyanamide and 2-[2-Cyanoimino-3-(1-cyclooctyl-piperidin-4-yl)-2,3-dihydro-benzoimidazol-1-yl]-acetamide | EURO-CELTIQUE S.A. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080200472-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2008-08-21 | — | — | US | disclosed |
| US-7414062-B2 | Triazaspiro compounds useful for treating or preventing pain | PURDUE PHARMA L.P. (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2008098019-A2 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | CARBYLAN BIOSURGERY, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1718315-A4 | HIGH DOSE, SHORT INTERVAL USE OF SULFATED POLYSACCHARIDES FOR THE TREATMENT OF INFECTIONS | UNIV MONASH (AU) | 2008-08-13 | — | — | EP | disclosed |
| US-20080188539-A1 | RAMIPRIL-AMINO ACID SALTS | SELAMINE LIMITED (IE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188466-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008095086-A2 | TOPIRAMATE PLUS NALTREXONE FOR THE TREATMENT OF ADDICTIVE DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1951718-A1 | 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF | Purdue Pharma LP (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1385518-B1 | BENZIMIDAZOLONE COMPOUNDS | EURO CELTIQUE SA (LU) | 2008-08-06 | — | — | EP | disclosed |
| EP-1385515-B1 | SPIROPYRAZOLE COMPOUNDS | EURO CELTIQUE SA (LU) | 2008-08-06 | — | — | EP | disclosed |
| EP-1803718-B1 | 4-Tetrazolyl-4-phenylpiperidine derivatives for treating pain | EURO CELTIQUE SA (LU) | 2008-07-23 | — | — | EP | disclosed |
| US-20080171775-A1 | RAMIPRIL-AMLODIPINE SALT | SELAMINE LIMITED (IE) | 2008-07-17 | — | — | US | disclosed |
| EP-1943250-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-07-16 | — | — | EP | disclosed |
| US-20080167364-A1 | RAMIPRIL-AMINE SALTS | SELAMINE LIMITED (IE) | 2008-07-10 | — | — | US | disclosed |
| EP-1942106-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2008-07-09 | — | — | EP | disclosed |
| EP-1664041-B1 | PHENYL-CARBOXAMIDE COMPOUNDS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2008-07-02 | — | — | EP | disclosed |
| CN-101212968-A | 3, 5-disubstituted and 3,5, 7-trisubstituted-3H-oxazolo and 3H-thiazolo [4, 5-d ] pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS INC (US) | 2008-07-02 | — | — | CN | disclosed |
| WO-2008077092-A2 | COMBINED EFFECTS OF TOPIRAMATE AND ONDANSETRON ON ALCOHOL CONSUMPTION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153835-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2008-06-26 | — | — | US | disclosed |
| EP-1549141-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING CLOFARABINE | BIOENVISION INC (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008073982-A2 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073987-A1 | SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1930322-A1 | 1-(4-piperidinyl)-1,3-dihydro-2H-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and ORL1 ligands for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2008-06-11 | — | — | EP | disclosed |
| CN-100393713-C | Therapeutic agents useful for treating pain | EURO CELTIQUE SA (LU) | 2008-06-11 | — | — | CN | disclosed |
| WO-2008065424-A1 | RAMIPRIL-AMLODIPINE SALT | SELAMINE LTD (IE) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008065431-A1 | RAMIPRIL-AMINE SALTS | SELAMINE LTD (IE) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008065421-A1 | RAMIPRIL-METAL SALTS | SELAMINE LTD (IE) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008065417-A1 | RAMIPRIL-AMINO ACID SALTS | SELAMINE LTD (IE) | 2008-06-05 | — | — | WO | disclosed |
| EP-1927858-A1 | Conformationally constrained peptides that bind the ORL-1 receptor | EURO-CELTIQUE S.A. (LU) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008053352-A2 | PHENYLPROPIONAMIDE COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (DE) | 2008-05-08 | — | — | WO | disclosed |
| US-20080107720-A1 | Topical delivery of codrugs | PSIVIDA, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1918279-A2 | 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and opioid receptor like receptor (ORL1) ligands for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2008-05-07 | — | — | EP | disclosed |
| US-20080090814-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| EP-1583763-B1 | BENZOAZOLYLPIPERAZINE DERIVATIVES HAVING VR1-ANTAGONIST ACTIVITY | EURO CELTIQUE SA (LU) | 2008-03-26 | — | — | EP | disclosed |
| US-20080070852-A1 | 3-Beta-D-Ribofuranosylthiazolo[ 4,5-D] Pyridimine Nucleosides and Uses Thereof | ANADYS PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| EP-1534303-A4 | ANTIMICROBIAL CHARGED POLYMERS THAT EXHIBIT RESISTANCE TO LYSOMAL DEGRADATION DURING KIDNEY FILTRATION AND RENAL PASSAGE, COMPOSITIONS AND METHOD OF USE THEREOF | UNIV MONASH (AU) | 2008-03-19 | — | — | EP | disclosed |
| US-7342017-B2 | 1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful for treating pain, depression and anxiety | EURO-CELTIQUE S.A. (LU) | 2008-03-11 | — | — | US | disclosed |
| CN-101137651-A | Pyridazinone compounds | ANADYS PHARMACEUTICALS INC (US) | 2008-03-05 | — | — | CN | disclosed |
| US-20080032999-A1 | Prodrugs of 5-amino-3-(3'-deoxy-b-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione | ANADYS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080020989-A1 | CARBONATE AND CARBAMATE PRODRUGS OF THIAZOLO[4,5-d]PYRIMIDINES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| WO-2008011406-A2 | CARBONATE AND CARBAMATE PRODRUGS OF THIAZOLO [4,5-D] PYRIMIDINES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1556354-B1 | THERAPEUTIC PIPERAZINE DERIVATES USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2008-01-23 | — | — | EP | disclosed |
| US-7321033-B2 | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
| US-20080004236-A1 | High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections | COMPER WAYNE D | 2008-01-03 | — | — | US | disclosed |
| WO-2007150002-A2 | PRODRUGS OF 5-AMINO-3-(3'-DEOXY-β-D-RIBOFURANOSYL)-THIAZOLO[4,5-d] PYRIMIDIN-2,7-DIONE | ANADYS PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007150001-A1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-1867644-A1 | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain | EURO-CELTIQUE S.A. (LU) | 2007-12-19 | — | — | EP | disclosed |
| EP-1862458-A2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-12-05 | — | — | EP | disclosed |
| CN-100352816-C | Nociceptin analogs | EURO CELTIQUE SA (LU) | 2007-12-05 | — | — | CN | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| WO-2007118854-A1 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007114881-A1 | TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES | NEXBIO, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1487829-B1 | THIADIAZOLYLPIPERAZINE DERIVATIVES USEFUL FOR TREATING OR PREVENTING PAIN | EURO CELTIQUE SA (LU) | 2007-10-10 | — | — | EP | disclosed |
| US-7279493-B2 | cyanoiminopiperazines which inhibit vanilloid receptor 1 function in a cell | EURO-CELTIQUE S.A. | 2007-10-09 | — | — | US | disclosed |
| WO-2007110449-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE | EURO-CELTIQUE S.A. (LU) | 2007-10-04 | — | — | WO | disclosed |
| CN-101039701-A | Prodrugs and codrug comprising a biocleavable disulfide linker | NICHOLAS PIRAMAL INDIA LTD (IN) | 2007-09-19 | — | — | CN | disclosed |
| EP-1562932-B9 | 4-TETRAZOLYL-4-PHENYLPIPERIDINE DERIVATIVES FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2007-09-12 | — | — | EP | disclosed |
| EP-1824482-A1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | Anadys Pharmaceuticals, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1412368-B1 | SUGAR DERIVATIVES OF HYDROMORPHONE, DIHYDROMORPHINE AND DIHYDROISOMORPHINE, COMPOSITIONS THEREOF AND USES FOR TREATING OR PREVENTING PAIN | EURO CELTIQUE SA (LU) | 2007-08-29 | — | — | EP | disclosed |
| EP-1824847-A2 | PYRIDAZINONE COMPOUNDS | Anadys Pharmaceuticals, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| CN-101024614-A | Analysis method for use in gas-phase chromatogram of esterization, cycle compounding process in production of cyclo-ammonium | NEIMONGYOL NORMAL UNIV (CN) | 2007-08-29 | — | — | CN | disclosed |
| US-7262194-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2007-08-28 | — | — | US | disclosed |
| US-20070190163-A1 | Technology for preparation of macromolecular microspheres | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTE OF HEALTH | 2007-08-16 | — | — | US | disclosed |
| US-7256193-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-08-14 | — | — | US | disclosed |
| EP-1631285-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2007-08-08 | — | — | EP | disclosed |
| US-20070179141-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2007-08-02 | — | — | US | disclosed |
| WO-2007085357-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-02 | — | — | WO | disclosed |
| EP-1810970-A1 | Therapeutic piperazine compounds | EURO-CELTIQUE S.A. (LU) | 2007-07-25 | — | — | EP | disclosed |
| EP-1807033-A2 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1803718-A1 | 4-Tetrazolyl-4-phenylpiperidine derivatives for treating pain | Euro-Celtique, S.A. (LU) | 2007-07-04 | — | — | EP | disclosed |
| US-20070142360-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2007-06-21 | — | — | US | disclosed |
| EP-1711484-A4 | SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES | EURO CELTIQUE SA (LU) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| EP-1789091-A2 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | Nicholas Piramal India Limited (IN) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007057229-A1 | 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| CN-1964985-A | 3-beta-D-ribofuranosyl thiazolo [4, 5-D ] pyrimidine nucleosides and uses thereof | ANADYS PHARMACEUTICALS INC (US) | 2007-05-16 | — | — | CN | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082041-A1 | Topical delivery of codrugs | PSIVIDA INC. (US) | 2007-04-12 | — | — | US | disclosed |
| US-7202259-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-04-10 | — | — | US | disclosed |
| EP-1768647-A1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENT | Virun, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1562932-B1 | 4-TETRAZOLYL-4-PHENYLPIPERIDINE DERIVATIVES FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2007-04-04 | — | — | EP | disclosed |
| US-7199151-B2 | DHA-pharmaceutical agent conjugates of taxanes | LUITPOLD PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| WO-2007028638-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-03-15 | — | — | WO | disclosed |
| EP-1562936-B1 | THERAPEUTIC PIPERAZINE COMPOUNDS | EURO CELTIQUE SA (LU) | 2007-03-14 | — | — | EP | disclosed |
| EP-1758916-A1 | 3-BETA-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | Anadys Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| CN-1917897-A | Composition and methods for modulating cns activity | CURIS INC (US) | 2007-02-21 | — | — | CN | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20070032500-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-08 | — | — | US | disclosed |
| US-20070027109-A1 | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof | MONASH UNIVERSITY | 2007-02-01 | — | — | US | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
| US-7157462-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-01-02 | — | — | US | disclosed |
| EP-1727801-A1 | PIPERAZINES USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2006-12-06 | — | — | EP | disclosed |
| EP-1727520-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1725222-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | Pharmacia Corporation (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060258669-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2006-11-16 | — | — | US | disclosed |
| US-7135491-B2 | 5-Aryltetrazole compounds and uses thereof | INOTEK PHARMACEUTICALS CORP. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1718315-A1 | HIGH DOSE, SHORT INTERVAL USE OF SULFATED POLYSACCHARIDES FOR THE TREATMENT OF INFECTIONS | Monash University (AU) | 2006-11-08 | — | — | EP | disclosed |
| EP-1631285-A4 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2006-11-02 | — | — | EP | disclosed |
| CN-1856484-A | Heteroaryl-tetrahydropyridinyl compounds for the treatment or prevention of pain | EURO CELTIQUE SA (LU) | 2006-11-01 | — | — | CN | disclosed |
| US-20060241117-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2006-10-26 | — | — | US | disclosed |
| US-20060235022-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2006-10-19 | — | — | US | disclosed |
| US-20060235055-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2006-10-19 | — | — | US | disclosed |
| EP-1711484-A1 | SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES | EURO-CELTIQUE S.A. (LU) | 2006-10-18 | — | — | EP | disclosed |
| US-7122198-B1 | Fast dissolving composition with prolonged sweet taste | PANACEA BIOTEC LIMITED (IN) | 2006-10-17 | — | — | US | disclosed |
| US-20060205674-A2 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS | NICHOLAS PIRAMAL INDIA LTD. (IN) | 2006-09-14 | — | — | US | disclosed |
| US-20060199824-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2006-09-07 | — | — | US | disclosed |
| CN-1829708-A | Piperidine compounds and pharmaceutical compositions containing them | EURO CELTIQUE SA (LU) | 2006-09-06 | — | — | CN | disclosed |
| EP-1694353-A2 | COMPOSITION AND METHODS FOR MODULATING CNS ACTIVITY | Curis, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060189602-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-7087631-B2 | Aryltetrazole compounds, and compositions thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-7078423-B2 | 5-Aryltetrazole compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-07-18 | — | — | US | disclosed |
| US-20060148814-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2006-07-06 | — | — | US | disclosed |
| US-7071335-B2 | 2-pyridinyl-1-piperazine therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2006-07-04 | — | — | US | disclosed |
| WO-2006066079-A2 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006066080-A1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060135519-A2 | 5-ARYLTETRAZOLE COMPOUNDS AND COMPOSITIONS THEREOF | NIVOROZHKIN ALEXANDER | 2006-06-22 | — | — | US | disclosed |
| US-20060135463-A1 | Methods and compositions for the treatment of lupus using clofarabine | WOOD CHRISTOPHER B | 2006-06-22 | — | — | US | disclosed |
| EP-1670447-A1 | MODAFINIL MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS | CEPHALON, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20060128717-A1 | Cycloheteroalkenyl compounds used as analgesics and for treating incontinence, inflammatory bowel disease, Parkinson's disease, amyotrophic lateral sclerosis, dementia, epilepsy, retinopathy, pruritus, psychoses, Huntington's disease, headaches, vomiting, dyskinesia or as anxiolytics and antidepressants | PURDUE PHARMA L.P. | 2006-06-15 | — | — | US | disclosed |
| EP-1667694-A2 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | Anadys Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1664041-A1 | PHENYL-CARBOXAMIDE COMPOUNDS USEFUL FOR TREATING PAIN | Euro-Celtique S.A. (LU) | 2006-06-07 | — | — | EP | disclosed |
| EP-1664016-A2 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | Euro-Celtique S.A. (LU) | 2006-06-07 | — | — | EP | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| US-20060100167-A1 | Methods and compositions for the treatment of autoimmune disorders using clofarabine | WOOD CHRISTOPHER B | 2006-05-11 | — | — | US | disclosed |
| WO-2006044206-A2 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING | NOVEN PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1648878-A1 | PIPERIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Euro-Celtique S.A. (LU) | 2006-04-26 | — | — | EP | disclosed |
| EP-1648880-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | Euro-Celtique S.A. (LU) | 2006-04-26 | — | — | EP | disclosed |
| US-20060084631-A1 | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof | MONASH UNIVERSITY | 2006-04-20 | — | — | US | disclosed |
| US-20060078604-A1 | Transdermal drug delivery device including an occlusive backing | NOVEN PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
| US-7026360-B1 | Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients | INPHARMA S.A. (CH) | 2006-04-11 | — | — | US | disclosed |
| US-20060074090-A1 | 1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful for treating pain, depression and anxiety | EURO-CELTIQUE S.A. | 2006-04-06 | — | — | US | disclosed |
| EP-1509523-A4 | TRIAZASPIRO COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | EURO CELTIQUE SA (LU) | 2006-04-05 | — | — | EP | disclosed |
| EP-1641775-A1 | 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN | Euro-Celtique S.A. (LU) | 2006-04-05 | — | — | EP | disclosed |
| CN-1753890-A | Benzoxazole piperazine derivatives with MGLUR 1-and MGLUR 5-antagonistic activity | EURO CELTIQUE SA (LU) | 2006-03-29 | — | — | CN | disclosed |
| WO-2006027711-A2 | PRODRUGS AND CODRUGS CONTAINING BIO- CLEAVABLE DISULFIDE LINKERS | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-03-16 | — | — | WO | disclosed |
| EP-1633338-A1 | COMBINATION OF THE ANALEPTIC MODAFINIL AND AN ANTIDEPRESSANT FOR THE TREATMENT OF DEPRESSION | CEPHALON, INC. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1631285-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | Euro-Celtique, S.A. (LU) | 2006-03-08 | — | — | EP | disclosed |
| US-20060046967-A1 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited (IN) | 2006-03-02 | — | — | US | disclosed |
| EP-1628652-A1 | COMBINATION OF THE ANALEPTIC MODAFINIL AND AN ANTIDEPRESSANT FOR THE TREATMENT OF DEPRESSION | CEPHALON, INC. (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-6995168-B2 | Triazaspiro compounds useful for treating or preventing pain | EURO-CELTIQUE S.A. (LU) | 2006-02-07 | — | — | US | disclosed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | disclosed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009825-A1 | COMPOSITIONS COMPRISING A MUCOADHESIVE PROTEIN AND AN ACTIVE PRINCIPLE FOR MUCOSAL DELIVERY OF SAID AGENTS | VIRUN, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006003521-A1 | HIGH DOSE, SHORT INTERVAL USE OF SULFATED POLYSACCHARIDES FOR THE TREATMENT OF INFECTIONS | MONASH UNIVERSITY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006001815-A1 | ACTIVE AGENTS USING LIPOSOME MACRO-BEADS | SUVANPRAKORN PICHIT (TH) | 2006-01-05 | — | — | WO | disclosed |
| EP-1021204-B1 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMA (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005121162-A1 | 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050281772-A1 | Compositions for mucosal delivery of agents | VIRUN, INC. | 2005-12-22 | — | — | US | disclosed |
| CN-1711256-A | 4-tetrazolyl-4-phenylpiperidine derivatives for the treatment of pain | EURO CELTIQUE SA (LU) | 2005-12-21 | — | — | CN | disclosed |
| US-6974818-B2 | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2005-12-13 | — | — | US | disclosed |
| EP-1598339-A1 | 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO-CELTIQUE S.A. (LU) | 2005-11-23 | — | — | EP | disclosed |
| EP-1598338-A1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO-CELTIQUE S.A. (LU) | 2005-11-23 | — | — | EP | disclosed |
| EP-1598340-A1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-BENZOXAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO-CELTIQUE S.A. (LU) | 2005-11-23 | — | — | EP | disclosed |
| CN-1701071-A | Therapeutic agents useful for treating pain | EURO CELTIQUE SA (LU) | 2005-11-23 | — | — | CN | disclosed |
| EP-1379252-A4 | NOCICEPTIN ANALOGS | EURO CELTIQUE SA (LU) | 2005-11-02 | — | — | EP | disclosed |
| US-20050234084-A1 | Triazaspiro compounds useful for treating or preventing pain | EURO-CELTIQUE S.A. | 2005-10-20 | — | — | US | disclosed |
| US-20050234024-A1 | Materials and methods for the treatment of ulcerative colitis | JOYCE CLARKE LIVING TRUST AGREEMENT, THE | 2005-10-20 | — | — | US | disclosed |
| EP-1499888-A4 | CONFORMATIONALLY CONSTRAINED PEPTIDES THAT BIND THE ORL-1 RECEPTOR | EURO CELTIQUE SA (LU) | 2005-10-19 | — | — | EP | disclosed |
| EP-1583763-A1 | BENZOAZOLYPIPERAZINE DERIVATIVES HAVING MGLUR1- AND MGLUR5-ANTAGONISTIC ACTIVITY | Euro-Celtique S.A. (LU) | 2005-10-12 | — | — | EP | disclosed |
| EP-1385518-A4 | BENZIMIDAZOLONE COMPOUNDS | EURO CELTIQUE SA (LU) | 2005-10-05 | — | — | EP | disclosed |
| CN-1678585-A | therapeutic agent for treating pain | EURO CELTIQUE SA (LU) | 2005-10-05 | — | — | CN | disclosed |
| US-6951860-B2 | Calcium channel blockers | MASSACHUSETTS COLLEGE OF PHARMACY (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1379246-A4 | NOCICEPTIN ANALOGS | EURO CELTIQUE SA (LU) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005084654-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | PHARMACIA CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050203014-A1 | Composition and methods for modulating CNS activity | CURIS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050192307-A1 | Benzimidazolone compounds | GOEHRING R R (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050181041-A1 | Method of preparation of mixed phase co-crystals with active agents | MEDCRYSTALFORMS, LLC (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005075459-A1 | SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES | EURO-CELTIQUE S.A. (LU) | 2005-08-18 | — | — | WO | disclosed |
| EP-1562932-A1 | 4-TETRAZOLYL-4-PHENYLPIPERIDINE DERIVATIVES FOR TREATING PAIN | Euro-Celtique, S.A. (LU) | 2005-08-17 | — | — | EP | disclosed |
| EP-1562936-A2 | THERAPEUTIC PIPERAZINE COMPOUNDS | Euro-Celtique, S.A. (LU) | 2005-08-17 | — | — | EP | disclosed |
| EP-1556354-A2 | THERAPEUTIC PIPERAZINE DERIVATES USEFUL FOR TREATING PAIN | Euroceltique S.A. (LU) | 2005-07-27 | — | — | EP | disclosed |
| US-20050159418-A1 | 5-Aryltetrazoles compounds and compositions thereof | NIVOROZHKIN ALEX (US) | 2005-07-21 | — | — | US | disclosed |
| US-20050159467-A1 | 5-Aryltetrazole compounds and uses thereof | NIVOROZHKIN ALEX (US) | 2005-07-21 | — | — | US | disclosed |
| WO-2005066130-A1 | PIPERAZINES USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-07-21 | — | — | WO | disclosed |
| US-20050159452-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2005-07-21 | — | — | US | disclosed |
| EP-1551386-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LUPUS USING CLOFARABINE | Bioenvision, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005061002-A2 | COMPOSITION AND METHODS FOR MODULATING CNS ACTIVITY | CURIS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050148580-A1 | Nociceptin analogs | PURDUE PHARMA L.P | 2005-07-07 | — | — | US | disclosed |
| EP-1549141-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING CLOFARABINE | Bioenvision, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005056524-A2 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005055983-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1542980-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | Inotek Pharmaceuticals Corporation (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1542991-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | Euro-Celtique, S.A. (LU) | 2005-06-22 | — | — | EP | disclosed |
| US-20050118242-A1 | Androgen pharmaceutical composition and method for treating depression | LABORATORIES BESINS INTERNATIONAL, SAS (FR) | 2005-06-02 | — | — | US | disclosed |
| EP-1534303-A1 | ANTIMICROBIAL CHARGED POLYMERS THAT EXHIBIT RESISTANCE TO LYSOMAL DEGRADATION DURING KIDNEY FILTRATION AND RENAL PASSAGE, COMPOSITIONS AND METHOD OF USE THEREOF | Monash University (AU) | 2005-06-01 | — | — | EP | disclosed |
| US-20050095294-A1 | Modafinil modified release pharmaceutical compositions | CEPHALON, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| EP-1158973-B1 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIV CINCINNATI (US) | 2005-05-04 | — | — | EP | disclosed |
| WO-2005035500-A2 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-04-21 | — | — | WO | disclosed |
| EP-1385514-A4 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2005-04-13 | — | — | EP | disclosed |
| WO-2005030753-A2 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030766-A1 | PHENYL - CARBOXAMIDE COMPOUNDS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-04-07 | — | — | WO | disclosed |
| US-20050074487-A1 | Transdermal and topical administration of drugs using basic permeation enhancers | DERMATRENDS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050070556-A1 | 3-B-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | US | disclosed |
| WO-2005027890-A1 | MODAFINIL MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS | CEPHALON, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-6872733-B2 | Benzimidazolone compounds | EURO-CELTIQUE S.A. (LU) | 2005-03-29 | — | — | US | disclosed |
| WO-2005025583-A2 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050059671-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2005-03-17 | — | — | US | disclosed |
| US-6867222-B2 | Nociceptin analogs | EURO-CELTIQUE, S.A. (LU) | 2005-03-15 | — | — | US | disclosed |
| US-20050054590-A1 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
| US-6864261-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2005-03-08 | — | — | US | disclosed |
| EP-1509523-A2 | TRIAZASPIRO COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | Euroceltique S.A. (LU) | 2005-03-02 | — | — | EP | disclosed |
| US-6861421-B2 | Nociceptin analogs | EURO-CELTIQUE S.A (LU) | 2005-03-01 | — | — | US | disclosed |
| WO-2005012287-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005009987-A1 | PIPERIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EURO-CELTIQUE S.A. (LU) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005007641-A1 | 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-01-27 | — | — | WO | disclosed |
| EP-1499888-A2 | CONFORMATIONALLY CONSTRAINED PEPTIDES THAT BIND THE ORL-1 RECEPTOR | Euro-Celtique S.A. (LU) | 2005-01-26 | — | — | EP | disclosed |
| WO-2005004882-A1 | ANTIVIRAL CHARGED POLYMERS THAT EXHIBIT RESISTANCE TO LYSOSOMAL DEGRADATION DURING KIDNEY FILTRATION AND RENAL PASSAGE, COMPOSITIONS AND METHODS OF USE THEREOF | MONASH UNIVERSITY (AU) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005004866-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2005-01-20 | — | — | WO | disclosed |
| US-20050009782-A1 | Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof | TRIDENT GROWTH FUND, LP | 2005-01-13 | — | — | US | disclosed |
| US-20050009854-A1 | Triazaspiro compounds useful for treating or preventing pain | EURO-CELTIQUE, S.A. | 2005-01-13 | — | — | US | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040259775-A1 | Conformationally constrained peptides that bind the ORL-1 receptor | EURO-CELTIQUE S.A. | 2004-12-23 | — | — | US | disclosed |
| EP-1487829-A1 | THIADIAZOLYLPIPERAZINE DERIVATIVES USEFUL FOR TREATING OR PREVENTING PAIN | Euro-Celtique S.A. (LU) | 2004-12-22 | — | — | EP | disclosed |
| US-6828440-B2 | Analgesics; side effect reduction | EURO-CELTIQUE, S.A. (LU) | 2004-12-07 | — | — | US | disclosed |
| WO-2004103305-A2 | SPIROPYRAZOLE COMPOUND | EUROCELTIQUE S.A. (LU) | 2004-12-02 | — | — | WO | disclosed |
| US-20040242698-A1 | Analeptic and antidepressant combinations | CEPHALON INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004100937-A1 | COMBINATION OF THE ANALEPTIC MODAFINIL AND AN ANTIDEPRESSANT FOR THE TREATMENT OF DEPRESSION | CEPHALON, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004100939-A1 | COMBINATION OF THE ANALEPTIC MODAFINIL AND AN ANTIDEPRESSANT FOR THE TREATMENT OF DEPRESSION | CEPHALON, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040235853-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2004-11-25 | — | — | US | disclosed |
| WO-2004100938-A1 | COMBINATION OF THE ANALEPTIC MODAFINIL AND AN ANTIDEPRESSANT FOR THE TREATMENT OF DEPRESSION | CEPHALON, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004100940-A1 | COMBINATION OF THE ANALEPTIC MODAFINIL AND AN ANTIDEPRESSANT FOR THE TREATMENT OF DEPRESSION | CEPHALON, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040229942-A1 | Analeptic and antidepressant combinations | CEPHALON INC | 2004-11-18 | — | — | US | disclosed |
| US-20040229941-A1 | Analeptic and antidepressant combinations | CEPHALON, INC. | 2004-11-18 | — | — | US | disclosed |
| US-20040229940-A1 | Analeptic and antidepressant combinations | CEPHALON INC | 2004-11-18 | — | — | US | disclosed |
| US-20040224012-A1 | Topical application and methods for administration of active agents using liposome macro-beads | BIOPHILE CORPORATION LTD. (TH) | 2004-11-11 | — | — | US | disclosed |
| US-20040220262-A1 | Transdermal and topical administration of drugs using basic permeation enhancers | TECHNOLOGY RECOVERY SYSTEMS, LLC | 2004-11-04 | — | — | US | disclosed |
| EP-1472225-A2 | 2-PIPERAZINE-PYRIDINES USEFUL FOR TREATING PAIN | Euro-Celtique S.A. (LU) | 2004-11-03 | — | — | EP | disclosed |
| EP-1466628-A1 | DHA-pharmaceutical agent conjugates | Luitpold Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040186111-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2004-09-23 | — | — | US | disclosed |
| US-20040180916-A1 | Treatment of pain with combinations of nalbuphine and other kappa-opioid receptor agonists and opioid receptor antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-09-16 | — | — | US | disclosed |
| US-20040180949-A1 | conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue | PROTARGA, INC. | 2004-09-16 | — | — | US | disclosed |
| EP-1448231-A1 | TOPICAL DELIVERY OF CODRUGS | Control Delivery Systems, Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040152689-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE, S.A. | 2004-08-05 | — | — | US | disclosed |
| EP-1441635-A2 | STERILE, BREATHABLE PATCH FOR TREATING WOUND PAIN | EpiCept Corporation (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| EP-1438020-A2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN | EpiCept Corporation (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004058754-A1 | BENZOAZOLYPIPERAZINE DERIVATIVES HAVING MGLUR1- AND MGLUR5-ANTAGONISTIC ACTIVITY | EURO-CELTIQUE S.A. (LU) | 2004-07-15 | — | — | WO | disclosed |
| US-20040127501-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2004-07-01 | — | — | US | disclosed |
| WO-2004054511-A2 | ANALGESIC COMBINATION COMPRISING NALBUPHINE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-07-01 | — | — | WO | disclosed |
| EP-1385515-A4 | SPIROPYRAZOLE COMPOUNDS | EURO CELTIQUE SA (LU) | 2004-06-30 | — | — | EP | disclosed |
| US-20040116423-A1 | 5-Aryltetrazole compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-20040106625-A1 | cyanoiminopiperazines which inhibit vanilloid receptor 1 function in a cell | PURDUE PHARMA L.P. | 2004-06-03 | — | — | US | disclosed |
| WO-2004046132-A1 | 4-TETRAZOLYL-4PHENYLPIPERIDINE DERIVATIVES FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2004-06-03 | — | — | WO | disclosed |
| US-20040106589-A1 | Fatty acid-pharmaceutical agent conjugates | PROTARGA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| US-6740641-B2 | ADMINISTERING TO A PATIENT FOR TREATMENT OF THE PAIN A GLUCOSIDE OR GLUCURONIDE DERIVATIVE OF HYDROMORPHONE, DIHYDROMORPHINE, OR DIHYDROISOMORPHINE OR A PHARMACEUTICALLY ACCEPTABLE SALT | EURO-CELTIQUE, S.A. (LU) | 2004-05-25 | — | — | US | disclosed |
| US-20040087641-A1 | Antiinflammatory agents; diuretics; antidepressants; Alzheimer's disease | EURO-CELTIQUE (LU) | 2004-05-06 | — | — | US | disclosed |
| EP-1412368-A2 | SUGAR DERIVATIVES OF HYDROMORPHONE, DIHYDROMORPHINE AND DIHYDROISOMORPHINE, COMPOSITIONS THEREOF AND USES FOR TREATING OR PREVENTING PAIN | EURO-CELTIQUE S.A. (LU) | 2004-04-28 | — | — | EP | disclosed |
| US-20040076648-A1 | Topical compositions and methods for treating pain | EPICEPT CORPORATION | 2004-04-22 | — | — | US | disclosed |
| WO-2004029031-A2 | THERAPEUTIC PIPERAZINE COMPOUNDS | EURO-CELTQUE, S.A. (LU) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004028463-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LUPUS USING CLOFARABINE | BIOENVISION, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004029025-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING CLOFARABINE | BIOENVISION, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004029044-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | EURO-CELTIQUE, S.A. (LU) | 2004-04-08 | — | — | WO | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| US-20040053914-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| US-20040044003-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2004-03-04 | — | — | US | disclosed |
| WO-2004014400-A1 | ANTIMICROBIAL CHARGED POLYMERS THAT EXHIBIT RESISTANCE TO LYSOMAL DEGRADATION DURING KIDNEY FILTRATION AND RENAL PASSAGE, COMPOSITIONS AND METHOD OF USE THEREOF | MONASH UNIVERSITY (AU) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004011441-A1 | PYRIDAZINYLPIPERAZINE DERIVATIVES FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | disclosed |
| EP-1385518-A1 | BENZIMIDAZOLONE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2004-02-04 | — | — | EP | disclosed |
| EP-1385515-A1 | SPIROPYRAZOLE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2004-02-04 | — | — | EP | disclosed |
| EP-1385514-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | Euro-Celtique S.A. (LU) | 2004-02-04 | — | — | EP | disclosed |
| WO-2004009563-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20040019208-A1 | 5-Aryltetrazole Compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION | 2004-01-29 | — | — | US | disclosed |
| US-20040018241-A1 | Bioadhesive compositions and methods for topical administration of active agents | NOVEN PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20040009953-A1 | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof | TRIDENT GROWTH FUND, LP | 2004-01-15 | — | — | US | disclosed |
| EP-1379252-A2 | NOCICEPTIN ANALOGS | Euro-Celtique S.A. (LU) | 2004-01-14 | — | — | EP | disclosed |
| EP-1379246-A1 | NOCICEPTIN ANALOGS | Euro-Celtique S.A. (LU) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006091-A1 | Therapeutic agents useful for treating or preventing pain | PURDUE PHARMA L.P. | 2004-01-08 | — | — | US | disclosed |
| WO-2004002983-A2 | THERAPEUTIC PIPERAZINE DERIVATIVES USEFUL FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2004-01-08 | — | — | WO | disclosed |
| US-20040002482-A1 | Androgen pharmaceutical composition and method for treating depression | UNIMED PHARMACEUTICALS, LLC | 2004-01-01 | — | — | US | disclosed |
| WO-2003101953-A2 | TRIAZASPIRO COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | EURO-CELTIQUE, S.A (LU) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003093294-A2 | CONFORMATIONALLY CONSTRAINED PEPTIDES THAT BIND THE ORL-1 RECEPTOR | EURO-CELTIQUE S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003093236-A1 | 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
| US-6638528-B1 | Pressure-sensitive adhesive matrix comprising blend of polyacrylate, polysiloxane, polyisobutylene, polyisoprene, polyamide or polystyrene; and insoluble, non-adhesive ethyl cellulose; polyvinylpyrrolidone crystallization inhibitor | NOVEN PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-6638981-B2 | Oil-in-water emulsions comprising antidepressant, NMDA receptor antagonist, lipophilic component, water, surfactant; compositions induce local-anesthetic effect when topically administered to intact skin, treating neuropathic pain | EPICEPT CORPORATION | 2003-10-28 | — | — | US | disclosed |
| US-6635653-B2 | Modulating a pharmacological response from the ORL1 receptor for treating chronic pain | EURO-CELTIQUE S.A. (LU) | 2003-10-21 | — | — | US | disclosed |
| US-20030181416-A1 | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof | TRIDENT GROWTH FUND, LP | 2003-09-25 | — | — | US | disclosed |
| WO-2003074520-A1 | THIADIAZOLYLPIPERAZINE DERIVATIVES USEFUL FOR TREATING OR PREVENTING PAIN | EURO-CELTIQUE, S.A. (LU) | 2003-09-12 | — | — | WO | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2003066595-A2 | 2 - PIPERAZINE - PYRIDINES USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2003-08-14 | — | — | WO | disclosed |
| US-6602902-B2 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | PROTARGA, INC. | 2003-08-05 | — | — | US | disclosed |
| EP-1329225-A2 | Transdermal device containing polyvinylpyrrolidone as solubility enhancer | NOVEN PHARMACEUTICALS, INC. (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030124176-A1 | Transdermal and topical administration of drugs using basic permeation enhancers | DERMATRENDS, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030118528-A1 | Topical delivery of codrugs | CONTROL DELIVERY SYSTEMS, INC. | 2003-06-26 | — | — | US | disclosed |
| US-6576636-B2 | Treating a noncentral nervous system by administering a covalent conjugate of a C8-26, unbranched, naturally occurring fatty acid and a drug, provided the drug is not an adenosine receptor agonist/antagonist; anticarcinogenics | PROTARGA, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030104041-A1 | Transdermal and topical administration of drugs using basic permeation enhancers | DERMATRENDS, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003043657-A1 | TOPICAL DELIVERY OF CODRUGS | CONTROL DELIVERY SYSTEMS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-6562363-B1 | Bioadhesive compositions and methods for topical administration of active agents | NOVEN PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20030082214-A1 | Topical compositions and methods for treating pain | DISCOVER GROWTH FUND, LLC (VI) | 2003-05-01 | — | — | US | disclosed |
| WO-2003034900-A2 | STERILE, BREATHABLE PATCH FOR TREATING WOUND PAIN | EPICEPT CORPORATION (US) | 2003-05-01 | — | — | WO | disclosed |
| US-20030082225-A1 | Sterile, breathable patch for treating wound pain | EPICEPT CORPORATION | 2003-05-01 | — | — | US | disclosed |
| WO-2003030818-A2 | ACTIVE AGENTS USING LIPOSOME BEADS | SUVANPRAKORN PICHIT (TH) | 2003-04-17 | — | — | WO | disclosed |
| US-20030069249-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2003-04-10 | — | — | US | disclosed |
| US-20030068365-A1 | Compositions and methods for administration of active agents using liposome beads | BIOPHILE CORPORATION, LTD. (TH) | 2003-04-10 | — | — | US | disclosed |
| EP-0737066-B1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMA (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6541479-B1 | Derivatives of thiosalicylic acid and o-aminobenzoic acid | MASSACHUSETTS COLLEGE OF PHARMACY | 2003-04-01 | — | — | US | disclosed |
| US-20030059471-A1 | Oral delivery formulation | COMPTON BRUCE JON (US) | 2003-03-27 | — | — | US | disclosed |
| US-20030050257-A1 | Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain | PURDUE PHARMA L.P. | 2003-03-13 | — | — | US | disclosed |
| WO-2003015699-A2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN | EPICEPT CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003011881-A2 | SUGAR DERIVATIVES OF HYDROMORPHONE, DIHYDROMORPHINE AND DIHYDROISOMORPHINE, COMPOSITIONS THEREOF AND USES FOR TREATING OR PREVENTING PAIN | EURO-CELTIQUE, S.A. (LU) | 2003-02-13 | — | — | WO | disclosed |
| US-20030027834-A1 | Spiropyrazole compounds | PURDUE PHARMA L.P. | 2003-02-06 | — | — | US | disclosed |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | disclosed |
| US-20030013874-A1 | Nociceptin analogs | PURDUE PHARMA L.P | 2003-01-16 | — | — | US | disclosed |
| US-20030008886-A1 | Benzimidazolone compounds | PURDUE PHARMA L.P. | 2003-01-09 | — | — | US | disclosed |
| US-20020192302-A1 | Transdermal and topical administration of antidepressant drugs using basic enhancers | DERMATRENDS, INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002085355-A1 | SPIROPYRAZOLE COMPOUNDS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085354-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085357-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085291-A2 | NOCICEPTIN ANALOGS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085361-A1 | BENZIMIDAZOLONE COMPOUNDS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
| CN-1377282-A | Fatty acid-anticancer conjugates and uses thereof | PROTARGA INC (US) | 2002-10-30 | — | — | CN | disclosed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | LUITPOLD PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| US-20020004065-A1 | Compositions and methods to effect the release profile in the transdermal administration of active agents | KANIOS DAVID (US) | 2002-01-10 | — | — | US | disclosed |
| EP-1163011-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | Protarga Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| EP-1158973-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6323236-B2 | PSYCHOLOGICAL DISORDERS | UNIVERSITY OF CINCINNATI | 2001-11-27 | — | — | US | disclosed |
| US-20010023254-A1 | Psychological disorders | CINCINNATI, UNIVERSITY OF | 2001-09-20 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| US-6221383-B1 | BLEND OF AT LEAST TWO POLYMERS, OR AT LEAST ONE POLYMER AND A SOLUBLE POLYVINYLPYRROLIDONE, IN COMBINATION WITH A DRUG PROVIDES A PRESSURE-SENSITIVE ADHESIVE COMPOSITION FOR A TRANSDERMAL DRUG DELIVERY SYSTEM | NOVEN PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | disclosed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000053231-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | PROTARGA, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-1021204-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| EP-0863774-A2 | TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING ACTIVE AGENTS TO THE HUMAN BODY VIA THE SKIN | LTS LOHMANN Therapie-Systeme GmbH (DE) | 1998-09-16 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5780051-A | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use | DYNAGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0831806-A1 | MULTIDENTATE METAL COMPLEXES AND METHODS OF MAKING AND USING THEREOF | WASHINGTON UNIVERSITY (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| CN-1143318-A | Transdermal device containing polyvinylpyrrolidone as dissolution enhancer | NOVEN PHARMA (US) | 1997-02-19 | — | — | CN | disclosed |
| WO-1997004818-A2 | TRANSDERMAL THERAPEUTIC SYSGTEM FOR ADMINISTERING ACTIVE AGENTS TO THE HUMAN BODY VIA THE SKIN | LTS LOHMANN THERAPIE-SYSTEME GMBH (DE) | 1997-02-13 | — | — | WO | disclosed |
| WO-1996040108-A1 | MULTIDENTATE METAL COMPLEXES AND METHODS OF MAKING AND USING THEREOF | WASHINGTON UNIVERSITY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0737066-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | SMN1; SMN2 742/4885NPSR1 2437/4885TLR2 4010/4885 |
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | GRIN1, GRIK1, GRIN2B | SMN1; SMN2 25/4885NPSR1 547/4885TLR2 1741/4885 |
| US-20200239460-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV3 | SMN1; SMN2 3528/4885NPSR1 74/4885TLR2 172/4885 |
| US-20070179141-A1 | Therapeutic agents useful for treating pain | OPRL1, OPRK1, OGFR | SMN1; SMN2 1120/4885NPSR1 43/4885TLR2 906/4885 |
| US-20200325146-A1 | OPIOID KETAL COMPOUNDS AND USES THEREOF | OPRK1, OPRD1, OPRL1 | SMN1; SMN2 1706/4885NPSR1 68/4885TLR2 1517/4885 |
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | SMN1; SMN2 3480/4885NPSR1 844/4885TLR2 9/4885 |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | PGRMC2, PGRMC1, CYP3A43 | SMN1; SMN2 4590/4885NPSR1 1934/4885TLR2 3216/4885 |
| US-20110166344-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | DPYD, NQO1, MT-ND5 | SMN1; SMN2 752/4885NPSR1 881/4885TLR2 3693/4885 |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | SMN1; SMN2 867/4885NPSR1 107/4885TLR2 4388/4885 |
| US-20030118528-A1 | Topical delivery of codrugs | DSG1, CCR7, CUTA | SMN1; SMN2 3548/4885NPSR1 2806/4885TLR2 145/4885 |
| US-20120015954-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CDR2, GRIN1, HRH2 | SMN1; SMN2 17/4885NPSR1 382/4885TLR2 2337/4885 |
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | SMN1; SMN2 1551/4885NPSR1 2630/4885TLR2 3831/4885 |
| US-20040053914-A1 | Therapeutic agents useful for treating pain | SMN1; SMN2, OPRM1, PSEN1 | SMN1; SMN2 1/4885NPSR1 186/4885TLR2 4359/4885 |
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ACMSD, ACACA, ALDH1A1 | SMN1; SMN2 3587/4885NPSR1 4391/4885TLR2 1244/4885 |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | TRPA1, TRPV1, CACNA1B | SMN1; SMN2 2423/4885NPSR1 401/4885TLR2 2267/4885 |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | BMP2, CHERP, PUF60 | SMN1; SMN2 4288/4885NPSR1 1673/4885TLR2 708/4885 |
| US-10619209-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | SMN1; SMN2 3839/4885NPSR1 82/4885TLR2 2374/4885 |
| US-20170183337-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV3 | SMN1; SMN2 3528/4885NPSR1 74/4885TLR2 172/4885 |
| US-20030050257-A1 | Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain | SLC5A1, SLC5A2, SORD | SMN1; SMN2 1142/4885NPSR1 470/4885TLR2 3939/4885 |
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | SMN1; SMN2 2477/4885NPSR1 2053/4885TLR2 9/4885 |
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | SMN1; SMN2 1958/4885NPSR1 2906/4885TLR2 664/4885 |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | SMN1; SMN2 742/4885NPSR1 2437/4885TLR2 4010/4885 |
| US-20080090814-A1 | PYRIDAZINONE COMPOUNDS | HAVCR2, PLPBP, CYP3A43 | SMN1; SMN2 4120/4885NPSR1 3482/4885TLR2 821/4885 |
| US-20180280386-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | SMN1; SMN2 2187/4885NPSR1 65/4885TLR2 795/4885 |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | SMN1; SMN2 3839/4885NPSR1 82/4885TLR2 2374/4885 |
| US-20210220343-A1 | TREATMENT OF BURN PAIN BY TRPV1 MODULATORS | TRPV1, TRPA1, TRPV2 | SMN1; SMN2 3359/4885NPSR1 239/4885TLR2 226/4885 |
| US-20100069437-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | OPRL1, OPRK1, OGFR | SMN1; SMN2 1120/4885NPSR1 43/4885TLR2 906/4885 |
| US-20110009418-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | OPRL1, OPRK1, TRPV1 | SMN1; SMN2 368/4885NPSR1 94/4885TLR2 216/4885 |
| US-20130345211-A1 | Pyridine Compounds as Sodium Channel Blockers | SCN1B, CACNA1A, TRPV1 | SMN1; SMN2 451/4885NPSR1 145/4885TLR2 3426/4885 |
| US-20160024022-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX3, CACNA1A, P2RX4 | SMN1; SMN2 426/4885NPSR1 168/4885TLR2 4340/4885 |
| US-20110082152-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | OPRL1, OPRK1, OPRM1 | SMN1; SMN2 556/4885NPSR1 101/4885TLR2 687/4885 |
| US-20080255063-A1 | 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF | DPYD, TYMP, DCTD | SMN1; SMN2 915/4885NPSR1 3130/4885TLR2 448/4885 |
| US-20080319020-A1 | 4-Oxadiazolyl-Piperidine Compounds and Use Thereof | VIP, ALPI, OPRD1 | SMN1; SMN2 268/4885NPSR1 1526/4885TLR2 1137/4885 |
| US-20130338170-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | SMN1; SMN2 3999/4885NPSR1 119/4885TLR2 164/4885 |
| US-20040186111-A1 | Therapeutic agents useful for treating pain | HTR1A, HRH2, GRIN1 | SMN1; SMN2 53/4885NPSR1 355/4885TLR2 2919/4885 |
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | HAVCR2, IFNG, TPMT | SMN1; SMN2 4002/4885NPSR1 2910/4885TLR2 122/4885 |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | CACNA1B, ORAI1, CACNA1I | SMN1; SMN2 934/4885NPSR1 249/4885TLR2 2090/4885 |
| US-20090062263-A1 | treating hepatitis C virus infections; inhibitor of HCV NS5B polymerase; N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-5-(3-methyl-butyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-1,1-dioxo-1,4-dihydro-1(lambda 6)-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide; coadministering with additional therapeutic agent | HAVCR2, TPMT, CYP2B6 | SMN1; SMN2 2448/4885NPSR1 1986/4885TLR2 1257/4885 |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | ARRB1, FPR1, OPRL1 | SMN1; SMN2 899/4885NPSR1 209/4885TLR2 464/4885 |
| US-20140288092-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SCN1B, SCN2B, SCN1A | SMN1; SMN2 1069/4885NPSR1 98/4885TLR2 4080/4885 |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | FABP7, FADS2, ALOX5 | SMN1; SMN2 509/4885NPSR1 201/4885TLR2 1471/4885 |
| US-20110071192-A1 | Therapeutic Agents Useful for Treating Pain | GRIN1, GRIK1, GRIN2B | SMN1; SMN2 25/4885NPSR1 547/4885TLR2 1741/4885 |
| US-20080032999-A1 | Prodrugs of 5-amino-3-(3'-deoxy-b-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione | DCTD, DPYD, TYMP | SMN1; SMN2 3295/4885NPSR1 3257/4885TLR2 413/4885 |
| US-20080292588-A1 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES | CYP1B1, CYP2E1, DAZAP1 | SMN1; SMN2 3277/4885NPSR1 2641/4885TLR2 280/4885 |
| US-20100130499-A1 | BICYCLOHETEROARYL COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS | TRPV1, TRPA1, TRPV3 | SMN1; SMN2 3667/4885NPSR1 152/4885TLR2 83/4885 |
| US-20140206649-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | SMN1; SMN2 2187/4885NPSR1 65/4885TLR2 795/4885 |
| US-20110281876-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | OPRL1, OPRK1, TRPV1 | SMN1; SMN2 368/4885NPSR1 94/4885TLR2 216/4885 |
| US-20090297478-A1 | Methods and Compositions for the Treatment of Lupus Using Clofarabine | SSB, BCL9, IL2 | SMN1; SMN2 4036/4885NPSR1 3451/4885TLR2 1619/4885 |
| US-20130012541-A1 | Therapeutic Agents Useful for Treating Pain | ARRB1, FPR1, OPRL1 | SMN1; SMN2 899/4885NPSR1 209/4885TLR2 464/4885 |
| US-20140046018-A1 | BIODEGRADABLE POLYMER - BIOACTIVE MOIETY CONJUGATES | BMP2, MKI67, FGF2 | SMN1; SMN2 2388/4885NPSR1 416/4885TLR2 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.